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1ABSTRACT
Intracerebral hemorrhage (ICH) is a devastating form of stroke, and a catastrophic 
medical emergency with high mortality and morbidity. Its common risk factors 
include hypertension and smoking, but different underlying causes are numerous. 
Knowledge regarding clinical characteristics and outcome of young ICH patients is 
limited. The long-term human and economic consequences of ICH in this population, 
encompassing 10% of all ICH patients, are particularly devastating.
The aims of this study were to define the prevalence of risk factors, etiologic 
distribution, clinical picture, and early mortality of young patients with ICH, as 
well as to compare these to older population. The second goal was to investigate 
medical complications suffered in the acute course of ICH. Third, we defined long-
term mortality, functional outcome, and prevalence of post-stroke depression 
(PSD) among these patients. For this Thesis project, we collected detailed clinical, 
radiological, mortality and follow-up data on all consecutive patients between 16 
and 49 years of age with first-ever ICH treated at the Helsinki University Hospital 
(HUH) between 2000 and 2010. Results concerning the early course of ICH were 
compared to a series of ICH patients aged >49 years treated in HUH between 2005 
and 2010, the Helsinki ICH Study.
Median age was 42 years (interquartile range 34-47) and males comprised 59.5% 
of the 336 patients included. Annual incidence of ICH was 4.9 (95% confidence 
interval 4.5-5.3) per 100 000. The most prevalent risk factors were hypertension 
(29.8%) and smoking (22.3%). Compared to older ICH patients (n=921) hypertensive 
microangiopathy was less common (25.0% vs. 34.3%, P=0.002) and structural 
lesions more common (25.0% vs. 4.9%, P<0.001) assumed etiologies of ICH. The 
cause remained elusive in 32.1% of all young patients, and in 22.5% of those who 
underwent MRI and any angiography (n=89, P=0.023). 
Three-month mortality rate was lower among young patients compared to older 
ones, (17.0% vs. 32.7%, p<0.001). Hematoma volumes were similar across all ages 
(p=0.324) and it independently predicted mortality in older patients, but not in the 
young. More severe stroke initially, measured by the National Institutes of Health 
Stroke Scale (NIHSS) score, infratentorial hematoma location, hydrocephalus, 
herniation, and multiple hemorrhages associated with increased 3-month mortality. 
When adjusted for these factors as well as demographics, ICH volume, and the 
underlying cause, we found that surgical evacuation was associated with lower 
mortality (odds ratio 0.06; 95% confidence interval 0.02-0.21, P<0.001). In 
propensity-score matched analysis, case-fatality rates were three-fold in those treated 
conservatively (27.5% vs. 7.8%, P<0.001). The most common medical complications 
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included hyperglycemia (51%), hyponatremia (45%), hypopotassemia (32%), and 
infections (28%). Hyperglycemia was the only single complication independently 
associated with increased mortality (5.90, 2.25-15.48, P<0.001). However, three 
or more concomitant complications also associated with increased mortality (7.76, 
1.42-42.49, P=0.018).
Among the 268 one-month survivors, 1-year survival was 98.1% (95% confidence 
interval 96.2-100%), 5-year survival 93.2% (89.3-97.1%), and 10-year survival 88.8% 
(84.9-92.7%), with male gender (3.36, 1.28-8.80, P=0.014) and diabetes (2.64, 1.01-
6.89, P=0.047) being associated with mortality. Unfavorable outcome (modified 
Rankin Scale score 2-5) emerged in 49%, and was independently predicted by higher 
age (1.09 per one year, 1.03-1.15, P=0.002) stroke severity (1.17 per one NIHSS score 
point, 1.08-1.27, P<0.001), and intraventricular extension of hemorrhage (3.26, 
1.11-9.55, P=0.031). PSD was present among one out of four survivors of ICH at 
young age. Since only one out of ten currently used antidepressants, treatment of 
depression appears as an unmet need in young ICH survivors.
In summary, prevention and treatment of cardiovascular risk factors are vital 
in ICH prevention among young adults. Comprehensive diagnostic work-up and 
imaging are essential in identifying the underlying cause of ICH. The young seem 
to survive ICH better than the elderly, particularly if surgical hematoma evacuation 
is pursued. A holistic approach to prevent and treat associated complications, 
specifically hyperglycemia, is vital in regard of survival. Only half of the survivors 
reach favorable functional outcome. Therefore, more effective measures of 
rehabilitation and mental health must be developed to improve the quality of life 
of this patient population.
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1 INTRODUCTION
1 INTRODUCTION
Blood eruption into the brain parenchyma is designated intracerebral hemorrhage 
(ICH). It is a devastating form of stroke, often being a fatal disturbance in the brain 
circulation. Stroke accounts for the second highest number of deaths and the third 
highest number of disability-adjusted life-years (DALYs) worldwide.1,2 ICH covers 
10 to 30 % of all strokes.3-5 ICH is the most devastating of the main stroke subtypes 
with overall mortality of 40 to 50 %.6-15 The overall ICH incidence is an annual 25 
cases per 100.000/year, remaining steady during recent decades.16
In contrast to recent success in ischemic stroke prevention and acute treatment, 
no such significant improvement has occurred in the medical care of ICH.16 To 
limit further brain injury and to prevent and treat associated complications the 
acute care of ICS has remained mostly supportive.17 A proportion of patients receive 
neurosurgical treatment, but data are insufficient to constitute uniform guidelines. 
After acute-phase treatment, intensive multiprofessional rehabilitation often follows. 
Despite this, the independence rate among survivors lies between 12% and 39%.16 In 
addition to the prominent physical impact on the patients, substantial consequences 
for mental health emerge frequently.
ICH has long gone understudied in young adults. Only about a dozen mostly 
small young ICH cohorts have been published since the 1980s with their upper age 
limit 35 to 45 years. Regarding the upper age cut-off of ischemic or hemorrhagic 
stroke studies in the young, the most recent studies have applied 50 or even 55 as 
the limit – a fact likely resulting from increased longevity in industrialized countries. 
Patients in this age group suffer about 10% of all ICHs.16 
ICH in the young differs from that in the elderly in several important aspects: 
Their risk factor and etiological spectrum is different and more diverse. The young 
have fewer cardiovascular risk factors and preexisting chronic diseases. Importantly, 
many more quality-weighted life years will be lost in case severe ICH affects a young 
individual. Since the young patients are at their most productive age, and usually have 
under-aged children, the disease may result in profound long-term socioeconomic 
and humane consequences, including long sick leaves, early retirement, prolonged 
institutional care, and even death.18-20 
Further knowledge and accurate up-to-date data on young-adult ICH is vital. In 
this Thesis project we aimed to describe the incidence, distribution of underlying 
causes and risk factors, acute-phase course of treatment, associated complications, 
and short- and long-term outcome of ICH in the young. Further, we sought to 
identify baseline factors associated with outcome, as well as to analyze differences 
between the younger and older ICH patients. For these purposes, we designed 
a comprehensive database comprising detailed clinical, imaging, laboratory, and 
follow-up data on consecutive patients with first-ever ICH at age of 16 to 49.
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2.1 DEFINITION OF INTRACEREBRAL HEMORRHAGE
Non-traumatic ICH (hereafter referred to as “ICH”) is a subtype of stroke, a 
catastrophic cerebrovascular insult without an underlying head trauma as its cause.21 
Traumatic ICH, therefore, is never considered a stroke subtype. ICH is defined as 
“extravasation of blood into brain parenchyma”.5 Outburst of blood is the opposite 
of ischemic stroke, in which a cerebral artery is occluded. Both induce disturbance 
of neuronal function through different pathophysiological mechanisms in brain 
tissue resulting in abrupt onset of neurological symptoms and signs.
2.2 INCIDENCE OF ICH
Of all strokes ICH accounts for 10-30 %.3,12,22,23 In contrast to past advances with 
ischemic stroke prevention, ICH incidence has remained steady.4,16 According to 
ethnic origin, a fairly recent meta-analysis of 36 studies from 20 countries reported 
ICH incidence of 24.2 cases per 100 000 population per year in white people, 22.9 
in black people, 19.6 in Hispanic people, and 51.8 in Asian people.16 These changes 
are only partly explained by differences in educational attainment, socioeconomic 
status, and prevalence of vascular risk factors, such as hypertension, smoking, and 
alcohol consumption.24-29 Overall ICH incidence is 24.6 (range from 1.8 to 129.6) 
cases per 100 000 population per year, a discovery by the same meta-analysis, 
having remained steady since 1980, and having decreased only in few populations 
with improved access to medical care and blood-pressure control.16,30-34 
Incidence markedly increases with age: from annual 1.9 cases per 100 000 among 
people aged under 45 to 196.0 cases among those over 84.16 Studies have shown 
44.4 % of all ICH occurring at age over 60, median age of ICH patients being 
61, and incidence rates doubling every 10 years after age 35.8,35,36 A few studies 
showed that incidence of ICH was higher in winter than summer.37-41 Reason for 
this has remained unresolved, but climatic conditions acting as synchronizers to 
endogenous rhythms and thereby influencing periodic occurrence of pathological 
vascular events has been proposed as explanation.38,39 Blood pressure increases 
during colder months.42
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Incidence of ICH in Finland has been investigated in only few studies. One 
reported 31 cases annually per 100 000 on average, with substantial increase with 
age: incidence rate of 2 in those 30-39 years, and 222 in those over 80 years.43 
These results were later confirmed by another study reporting incidence rate of 27 
on average, and the mean age at incident being 70 years.44 Incidence of ICH has 
remained steady in Finland.45,46 As the proportion of the elderly increases in the 
future in Finland and other industrialized countries, ICH incidence is also expected 
to increase.47-49
2.3 ECONOMICAL IMPACT OF INTRACEREBRAL HEMORRHAGE 
The financial burden of ICH has been investigated in few countries.18-20,49-56 Because of 
the need for close monitoring for clinical deterioration or cardiorespiratory support 
due to impaired consciousness, patients most often need treatment in intensive care 
stroke unit (ICSU), intensive care unit (ICU), or neurosurgical treatment in the acute 
phase on the course of ICH. All these are much more expensive in comparison to 
regular hospital ward. After the patient has been stabilized, neurological hospital 
ward follows aiming to initiate multi-professional rehabilitation, and – depending on 
the underlying cause of ICH – commencing secondary prevention of ICH. Average 
in-hospital treatment of 7.7 days, estimated to cost $15,256, has been reported, with 
$1,569 for each additional day.54 Working-aged patients may need long sick-leaves, 
or even early retirement. Due to the loss of productivity, the financial burden of 
ICH of $125,000 per patient has been estimated, resulting in an overall cost of $6 
billion in the United States alone.50 Stroke, including hemorrhagic and ischemic 
stroke, have been estimated to cause annual direct and indirect costs of $816,1 
million in Finland.57
2.4 PATHOPHYSIOLOGY OF INTRACEREBRAL HEMORRHAGE
Instead of a single event, ICH is a dynamic process with three phases: 1) initial 
blood eruption, 2) hematoma expansion, and 3) development of perihematomal 
edema.58-61 The initial hemorrhage causes prominent amount of parenchymal 
damage as the hematoma bulk dissects along the white matter tissue planes of 
the brain, encircling islands of intact neural tissue.23,62 Animal models have failed 
to reveal secondary damage being caused by local mass effect.63 Expansion of 
hematoma due to continuing bleeding is usually defined as >12.5 ml or >33% 
increase in the hematoma volume. Hematoma expansion typically occurs during 
the few hours following initial hemorrhage and is associated with neurological 
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deterioration: in 26%, 36%, and 47% of the patients within 1, 3, and 24 hours 
after ictus, respectively.58,64-67 A more recent study showed that 73% of patients 
assessed within 3 hours from ictus have some degree of hematoma expansion, 
and 35% have clinically prominent expansion.68 Hematoma expansion is highly 
unlikely to result after 24 hours from ictus, and even 6 hours, if hematoma volume 
is <25 ml.58,69 It is still unclear what the mechanisms of early hematoma growth 
are, but it is likely related to sudden increases in intracranial pressure (ICP), which 
causes local tissue distortion and disruption, vascular engorgement secondary to 
obstructed venous outflow, blood-brain-barrier disruption, and a local coagulopathy 
secondary to release of tissue thromboplastin.5,70 Expansion of the hematoma is 
a common cause of early neurological deterioration, increased mortality, and 
poor functional outcome.68,71 The rate of expansion and the size of the original 
hematoma correlate with neurological deterioration. Antiplatelet therapy as well 
as use of oral anticoagulation (OAC) independently predict hematoma expansion.64 
Higher hematoma volume and IVH on admission associate with neurological 
deterioration.72,73 Diabetes, high systolic blood pressure on hospital arrival, and 
elevated C-reactive protein associate with hematoma expansion.69,74,75 Mortality 
increases exponentially when the hematoma volume exceeds 30ml; the 30-day 
mortality among patients with >60ml hematoma and Glasgow Coma Scale (GCS) 
score <9 is >90%, whereas only 19% for those with <30ml hematoma and a GCS 
score ≥9.10,76 Hematoma may extend to ventricular system containing cerebrospinal 
fluid (CSF) in up to 40% of the cases; this condition is defined as intraventricular 
hemorrhage (IVH), and associates with obstructive hydrocephalus and worsened 
prognosis.70
Perihematomal edema develops over many days and is the primary cause 
of neurological deterioration after the first day from ictus, by interfering with 
functioning of nearby brain areas, causing relative ischemia by compressing blood 
vessels, and by increasing intracranial pressure.72,77 It derives from plasma, is caused 
mainly by the inflammatory response secondary to local release of thrombin and 
other end products of coagulation from the hematoma, by cytotoxic mediators, 
by disruption of the blood-brain-barrier, sodium pump, and neurons.47,60,61,78-86 
Correlating with lysis of red blood cells, edema peaks around 3 to 7 days after onset, 
but has been observed to last even two weeks in experimental models.87,88 The degree 
of edema correlates with the hematoma volume.89 It has been implicated that both 
hemoglobin and its degradation products are directly and indirectly neurotoxic.90,91 
Retrospective evidence suggest that larger amount of cerebral edema relative to the 
initial hemorrhage correlates with worse clinical outcomes, but not independently 
from hematoma volume.89,92,93
No uniform consensus exists on the issue whether ICH is surrounded by 
ischemic penumbra, but a recent study found no evidence of potentially salvageable 
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ischemic penumbra in the acute phase after ICH, suggesting that perihematomal 
hypoperfusion is a consequence of reduced metabolic demand rather than tissue 
ischemia.94,95 It is more likely that perihemorrhagic tissue damage is primarily related 
to the inflammatory and cytotoxic response of tissue and vasculature of hemorrhage 
site, and that the impact of perihematomal ischemia is probably small.
2.5 RISK FACTORS OF INTRACEREBRAL HEMORRHAGE
Risk factors for ICH have been reported by multiple studies.32,96-98 The most 
important risk factor for ICH, as well as other stroke subtypes, is hypertension, 
commonly defined as systolic blood pressure >160 mmHg or diastolic blood pressure 
>110 mmHg.97,99,100 The severity and duration of hypertension have a clear correlation 
with the risk of ICH.96 Antihypertensive treatment in patients with hypertension 
decreases risk of stroke, including ICH.101,102 Male gender and higher age have also 
been reported as risk factors for ICH.5,96,97,103 Age-related degenerative changes in 
cerebral arteries increase the risk for rupture, but also for ischemic stroke. Women 
are protected by estrogen, which reduces the risk of all detrimental cardiovascular 
insults, such as myocardial infarction and ischemic stroke. One reason for this is, 
estrogen having a protective effect against atherosclerosis by mediating transportation 
of cholesterol.104-106 In addition, estrogen may have neuroprotective effects and 
induce recovery after ischemic stroke.107,108 The association of dyslipidemias or statin 
use and ICH has been subject to numerous studies and intensive debate in recent 
years, but remains conclusively unresolved. Hypocholesterolemia has been reported 
as risk factor for ICH in few studies.109-111 This association was not evident in other 
cohorts.112,113 Two more recent studies reported hypercholesterolemia as a risk factor 
for ICH.114,115 Hyper-LDL cholesterolemia and hypo-HDL cholesterolemia were also 
identified as possible risk factors, while triglyceridemia was not associated with 
ICH.115 The investigators proposed use of statins for a possible measure of secondary 
prevention of ICH. Their results, however, are in contrast to a previous study with 
similar number of ICH patients.116 Other previous studies have, however, reported 
statins as a risk factor for ICH and cerebral microbleeds, asymptomatic intracerebral 
bleeding seen with T2*-weighted MRI and risk factor for ICH themselves, and 
suggested avoiding statin use after a patient has suffered an ICH, especially one of 
lobar location.116-122 On the contrary, a recent meta-analysis found no association 
between statins and increased ICH prevalence, and another meta-analysis found 
no association between statin use and hematoma volume, mortality, or functional 
outcome after ICH.123,124 Preventative impact of statins on coronary heart event and 
ischemic stroke are proven, but safety on secondary prevention of ICH is still under 
debate and uniform guidelines are lacking.125 
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Smoking is another important risk factor for ICH, ischemic stroke, and SAH, 
with gradual increase depending on how many cigarettes are smoked.109,110,126 
This association seems to be independent from hypertension, but most likely 
also resulting from atherosclerosis and structural damage to the arterial wall.127,128 
Excessive alcohol use (>60 mg/d) too increases risk of ICH, partially because 
of alcohol-induced hypertension but also independently, and most likely due to 
impaired coagulation, thrombocyte dysfunction, and directly affecting the integrity 
of cerebral vasculature.96,129-135 Short-term moderate or heavy alcohol intake within 
24 hours or one week (binge drinking) causes higher risk for ICH in comparison 
to long-term habitual heavy drinking.133 
High-dose aspirin use also increases the risk of ICH, with 1300 mg or over 
daily causing 2-fold risk of ICH, but possible association with dipyridamole or 
clopidogrel remains unresolved due to contradictory findings.133,136-139 Absolute 
risk increase of 12 events per 10,000 persons associated with aspirin must be put 
in the context of the benefit of reduced risk of myocardial infarction (MI) and 
ischemic stroke.5,140 One study found no association between antiplatelet therapy 
and recurrent hemorrhage.141 OAC and fibrinolytic agents are a growing precipitant 
for secondary ICH accounting for nearly 20% of all ICH as long-term use of OAC 
increases the risk of ICH 7- to 10-fold.142-147 The risk of ICH roughly doubles as 
INR increases by one.5,148 OAC use on patients with history of ICH has been widely 
considered problematic dilemma, due to the risk of recurrent ICH, and high early 
mortality associated with it – even after reversal of vitamin K antagonist by vitamin 
K, and clotting factor replacement with prothrombin complex concentrate (PCC), or 
fresh frozen plasma.5,149-151 Some evidence exists that with a certain group of patients, 
those with deep hemispheric ICH at particularly high risk for thromboembolic insult 
or low risk of ICH recurrence, the benefit of long-term OAC outweighs the risks.152 
Another issue is the timing of re-initiation of OAC, which has been instructed to 
commence earliest between 7 to 14 days after ictus, but not enough data yet exists 
for strong recommendations.153-155 Relationship between both OAC and antiplatelet 
therapy with cerebral microbleeds has been shown, indicating the need for selecting 
those patients in lesser risk of recurrent ICH.156,157 Due to lack of data from RCTs, no 
uniform guidelines currently exists addressing antithrombotic or antiplatelet therapy 
after ICH, and treating physicians are left to make clinical decisions on the basis 
of indirect and observational evidence.150,158 Selective serotonin reuptake inhibitors 
also predispose ICH. Reports on nonaspirin nonsteroidal anti-inflammatory drugs 
(NSAID) being a risk factor for hemorrhagic or ischemic stroke have so far been 
contradictory, and further investigation is needed to draw conclusions.159-161
Genetic risk factors of ICH are still under investigation.162 A point mutation in 
the gene involved in the formation of factor XIII, responsible for fibrin cross-linking, 
has been reported to increase risk of ICH.163 Epistaxis has also been reported as 
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risk factor for ICH.136 Diabetes is a well-known risk factor for ischemic stroke.164-167 
It has been associated with ICH in few cohorts, but a meta-analysis of 8 case-
control studies could not confirm that association.96,168-170 More data are needed to 
draw conclusions whether diabetes is a risk factor for ICH. Prior ischemic stroke 
is a risk factor for ICH; prevalence of ischemic stroke among ICH patients of 29% 
has been reported.171 Chronic kidney disease has been proposed being a risk factor 
for ischemic stroke, and for ICH after thrombolysis of ischemic stroke, but no 
evidence has been reported it being a risk factor for spontaneous ICH.172-174 Finally, 
low socioeconomic status and level of education associate with higher incidence 
of stroke, ICH in particular, most likely resulting from unhealthy lifestyle habits 
and impaired compliance of treatment of hypertension.175,176 Risk factors of ICH 
are summarized in Table 1.
Table 1. Risk factors of intracerebral hemorrhage
Risk factor
Male gender
Age
Hypertension 
Smoking
Alcohol
Anticoagulant use
Antiplatelet use
Genetic factors
2.5.1 PREVENTION OF INTRACEREBRAL HEMORRHAGE
Due to its high morbidity, mortality, and lacking proven therapy, primary prevention 
of ICH is of paramount importance. Treatment of mild to moderate hypertension 
reduces the risk of stroke, including ICH, in middle-aged and elderly by 36% to 
48%.101,177-179 Treatment of chronic hypertension is probably the most effective means 
of preventing ICH.180 Results from Perindopril Protection Against Recurrent Stroke 
Study (PROGRESS) showed that perindopril plus optional indapamide significantly 
lowered the risk of ICH in patients with any cerebrovascular disease.181 Cessation of 
smoking and restrained use of alcohol are reasonable recommendations to prevent 
ischemic and hemorrhagic stroke.126,130,182-184 Patients for vitamin K antagonist 
anticoagulation should be carefully selected, and INR values on those selected 
patients regularly monitored.185-188 A recent meta-analysis showed that using 
novel oral anticoagulants instead of warfarin reduces incidence of ICH caused by 
anticoagulation by half.189 Patients for thrombolysis for myocardial infarction and 
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acute ischemic stroke should also be carefully selected.190-193 Physical activity reduces 
the risk of stroke.194 Increased daily consumption of fruits and vegetables may as 
well decrease the risk of stroke, including ICH.195
2.6 CAUSES OF INTRACEREBRAL HEMORRHAGE 
Intracerebral hemorrhage can be caused by numerous factors, classified in two 
groups – primary and secondary.23 Primary ICH, accounting for 78 to 88 % of 
all cases, occurs without any underlying congenital or acquired brain lesion or 
abnormality, whereas secondary ICH is directly related to a pre-existing intracranial 
abnormality or condition.5,23,35,47 High-quality studies defining the most likely 
cause for an ICH and including autopsy verification are scarce, and developing a 
comprehensive classification has been fairly recently acknowledged as a research 
priority.196 
2.6.1 PRIMARY INTRACEREBRAL HEMORRHAGE
Rupture of small penetrating arteries damaged by chronic hypertension is 
regarded responsible for approximately 70% of primary ICH, making hypertensive 
microangiopathy the most important cause.23,47,197-201 Approximately half of 
hypertension-related ICH locates deep, in the basal ganglia, thalamus, periventricular 
gray matter, or brain stem, 30% in superficial areas, and rest in cerebellum (Figure 
1).47,202,203 These areas are perfused by the thin perforating arteries that rise directly 
from the large basal cerebral arteries, and are directly exposed to the harmful effects 
of hypertension because they lack the protection of preceding gradual decrease 
in vessel caliber. This induces pathological changes such as degeneration in the 
vessel wall smooth muscle, which is replaced by collagen and intimal hyalinization, 
and development of small miliary aneurysms associated with thrombosis leading 
to microhemorrhages. The atherosclerotic changes, or “lipohyalinosis”, result 
in development of noncompliant narrowed vessels that are susceptible to both 
sudden occlusion (lacunar infarction) and rupture (ICH).23 Evidence with electron 
microscopy has shown that degeneration and bleeding occurs at or near the 
bifurcation of affected arteries.204 
Cerebral amyloid angiopathy (CAA), estimated to account for more than 20% 
of all ICH in patients older than 70 years, causes mainly lobar and subcortical 
hematomas (Figure 2).205-207 Distinct of systemic amyloidosis, it is characterized 
by accumulation of β-amyloid protein and degenerative changes in the media and 
adventitia of blood vessels of cerebral cortex and leptomeninges.47,187 CAA is highly 
18
2 REVIEW OF THE LITERATURE
associated with age, because over 60% of autopsy samples from patients older 
than 90 years exhibit some degree of amyloid deposition.23 Genetic variations of 
apolipoprotein Ee2 and Ee4 seem to associate with CAA.187,208-214 The Boston criteria, 
combining clinical, radiologic, and pathologic data, have been developed between 
1995 and 1996 to classify lobar ICH into categories of possible, probable, or definite 
likelihood of underlying CAA, and have since been validated.215-218 CAA is definitely 
evident only after pathological analysis revealing deposition of vascular amyloid, 
and probably evident in patients older than 55 years with multiple hemorrhages 
without other explanation. CAA is possible cause of ICH in patients older than 55 
years with single cortical or subcortical hemorrhage without another cause, multiple 
hemorrhages with a possible but not a definite cause, or some hemorrhage in an 
atypical location.
Figure 1. A deep-located ICH.
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Figure 2. An ICH of lobar location.
2.6.2 SECONDARY INTRACEREBRAL HEMORRHAGE
Due to their risk of bleeding, vascular structural anomalies are important causes 
of secondary ICH. Including arteriovenous malformation (AVM), cavernous 
hemangioma, intracranial aneurysms, and Moyamoya disease, they constitute 
approximately 5% of all ICH.23,219 Rupture of aneurysm causes 85% of SAHs, and 
also ICH may occur – mostly in cases with middle cerebral or distal anterior cerebral 
artery aneurysm.220 AVMs are vascular lesions, in which blood flows from arteries to 
veins without capillaries (Figures 3A and 3B.). They are most likely congenital but 
not hereditary, and their most common clinical presentation is ICH.221 The estimated 
annual rate of bleeding is between 2 to 3%.222 Cavernous hemangiomas, another type 
of vascular malformation, have less blood flow, and usually cause epilepsy. They 
carry, however, annual risk of ICH of 1 to 2%.223 Epithelioid hemangioendotheliomas 
and capillary telangiectasies are rare structural causes of ICH. Primary or metastatic 
intracranial neoplastic tumor may also bleed into brain parenchyma.5
Oral anticoagulation (OAC) associates nearly 20% of all ICHs, having markedly 
increased since 1990s as a result of increasing use of OAC to prevent ischemic events 
in patients with atrial fibrillation.71,143,144,187,224 Annual risk for ICH is between 0.3 
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Figures 3A and 3B. Left temporal ICH with intraventricular extension in a 22-year old woman 
seen in CT (3A) and the underlying AV-malformation seen in CT-angiography (3B).
3A
3B
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and 1.0% among patients under OAC.143 Most episodes of OAC-caused ICH often 
occur during international normalized ratio (INR) being between 2.0 and 3.5.225,226 
OAC use is associated with larger initial hematomas, hematoma expansion, and 
neurological deterioration in the first 24 to 48 hours.227,228 Recent evidence shows that 
OAC-related ICH is more often lobar than deep.229 Novel oral anticoagulants have 
substantially lower risk of ICH in comparison to traditional OAC.189 Other acquired 
coagulopathies include those related to liver diseases, such as liver cirrhosis, due to 
the decreased production of clotting factors I (fibrinogen), II (prothrombin), V, VII, 
VIII, IX, X, and XI. Rarely ICH may also be caused by hereditary coagulopathies, 
such as von Willebrand’s disease, or malignant hematological diseases, such as 
leukemia or polycythemia vera. Iatrogenic etiologies include carotid endarterectomy 
and heparin. Thrombolysis of myocardial infarction poses a risk of 1% for ICH.
Hemorrhagic transformation of ischemic stroke, the most feared complication 
of ischemic stroke and thrombolysis treatment, cerebral venous thrombosis 
(CVT), and intracranial vasculitis are also possible, but rare causes of ICH.190,191,230-
233 National Institute of Neurological Disorders and Stroke has reported that the 
overall risk of ICH after use of tissue plasminogen activator for ischemic stroke is 
6.4%.191,234,235 Eclampsia acutely raises blood pressure, and by the same mechanism, 
or by reversible cerebral vasoconstriction syndrome (RCVS), pheochromocytoma, 
glomerulonephritis, and strenuous physical activity, may also cause ICH.236-242 In all 
of these cases, hemorrhage is caused by pathologic circumstances in brain circulation 
and parenchyma. Finally, illicit drugs, such as amphetamine or cocaine, may also 
cause ICH by RVCS or necrotizing angiitis. One case has also been reported of ICH 
associated with ephedrine abuse.243 Causes of ICH are summarized in Table 2. If 
no cause of ICH is evident, it is considered cryptogenic.
2.6.3 CAUSES OF INTRACEREBRAL HEMORRHAGE IN THE YOUNG
ICH among young people has been studied in single-center studies (total n=1890) 
with the largest series including 404 patients (Table 3).110,244-254 Reflecting the 
different numbers of patients, geographic settings, and patients’ ethnic backgrounds, 
as well as the upper age cut-off chosen, the proportions of ICH etiologies have 
varied largely among these studies (Table 3). The proportion of ICHs caused by 
hypertensive microangiopathy has been from 11 to 79%, while structural causes 
have accounted from 17 to 65%. Previous reports suggest the young adults have a 
wide range of causes underlying ICH.246,247,249
22
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Table 2. Primary and secondary causes of intracerebral hemorrhage
Primary Secondary
Hypertensive microangiopathy Vascular malformations
Cerebral amyloid angiopathy Medication
Coagulopathy
Hematologic disorders
Vasculitis
Moyamoya disease
Cerebral venousthrombosis
Hemorrhagic transformation of cerebral infarct
Aneurysms
Tumor
Reperfusion after carotid endarterectomy
Thrombolysis
Illicit drugs
Reversible cerebral vasoconstriction syndrome
Other rare causes
2.7 CLINICAL PRESENTATION AND EVALUATION OF 
INTRACEREBRAL HEMORRHAGE
2.7.1 CLINICAL PICTURE OF INTRACEREBRAL HEMORRHAGE
The clinical presentation of ICH depends on its size and location as well as presence 
of IVH. The classic presentation of ICH is sudden onset of a focal neurological deficit 
that – in contrast to other stroke subtypes – progresses gradually over minutes to 
hours, with accompanying headache, nausea, vomiting, decreased consciousness, 
and elevated blood pressure.180,256 Gradual progression most likely relates to ongoing 
bleeding. Only 15% present symptoms at awakening.180 The most common symptom 
is headache of variable intensity and the most common focal neurological deficits 
include hemiparesis, dysarthria, and aphasia.23 Headache is present in about 40%.257 
Prevalence of vomiting has been reported 49% for ICH patients, but it is common 
in all stroke subtypes located in the posterior fossa (Figure 4).180 Clinical signs of 
increased ICP, such as early impaired consciousness, nausea, and vomiting are 
suggestive of ICH. Seizures appear in approximately 10% of all patients with ICH and 
in almost one half of patients with lobar hemorrhage. Nearly all seizures occur at the 
onset of bleeding or within the first days of ictus and are not strongly predictive of the 
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development of delayed epilepsy.258 More than 90% patients present with elevated 
blood pressure (>160/100 mmHg), and symptoms caused by dysautonomia, such 
as hyperventilation, tachycardia, bradycardia, central fever, and hyperglycemia are 
also frequent.5,259
Figure 4. ICH of infratentorial location (posterior fossa).
Large hemorrhages may cause coma due to increased ICP leading to decreased 
cerebral perfusion or due to direct infiltration or distortion of diencephalic or 
brainstem structures (Figure 5). Putaminal hemorrhages present with contralateral 
motor deficits, gaze paresis, aphasia, or hemineglect (Figure 6). Thalamic 
hemorrhages present with contralateral sensory loss; pupillary and oculomotor 
abnormalities are possible, especially if the thalamic hemorrhage extends into the 
rostral brainstem (Figure 7). Cerebellar hemorrhages present with nausea, vomiting, 
ataxia, nystagmus, decreased level of consciousness, and ipsilateral gaze palsies 
or facial paralysis (Figure 8). Pontine hemorrhages present with coma, pinpoint 
pupils, disturbed respiratory patterns, autonomic instability, quadriplegia, and gaze 
paralysis, and are commonly fatal. The presentation of lobar hemorrhages depends 
on the exact location of the hemorrhage.23 Blood extending into the ventricular 
system causes reduced level of alertness due to ventricular ependymal irritation 
or the development of hydrocephalus.23 Clinical deterioration develops in 30% to 
50% of patients, usually within 24 hours following ictus, and most often due to 
hematoma expansion.5,47,72,73,260,261 Deterioration occurring over 24 hours more often 
results due to increased edema surrounding ICH.262
25
Figure 5. A massive ICH compressing brain structures.
Figure 6. A putaminal ICH.
26
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Figure 7. A thalamic ICH with IVH.
Figure 8. A cerebellar ICH.
27
2.7.2 EARLY MORTALITY AFTER INTRACEREBRAL HEMORRHAGE
ICH is the most catastrophic subtype of strokes with high mortality and morbidity. 
Early mortality after ICH has been studied in multiple cohorts. A fairly recent 
meta-analysis concluded that case-fatality at 1 month was 40%, increasing to 54% 
at one-year.16,263 Investigators of individual cohorts have reported early mortality 
rates between 40% and 50 %, with half of deaths occurring within the first 2 
days.7,8,10,32,43,180,264-271 In Finland 3-month mortality after ICH is 35%.44 In young 
adults in-hospital or 1-month mortality after ICH was between 8% and 34% (Table 
3).110,244-254 In one cohort, 30% of the survivors after acute phase were left in a 
vegetative state, and in other reports only 20% to 25% of the survivors were fully 
independent at 6 months, with higher age decreasing this probability.265,269,272 
Factors predicting early mortality or poor functional outcome have been also 
investigated in several studies. Radiological and clinical characteristics indicating 
the severity of hemorrhage have been repeatedly reported to associate with the 
outcome. Daverat et al. found 30-day mortality being increased by higher hematoma 
volume, lateral shift of cerebral midline structures, and intraventricular hemorrhage 
(IVH).266 These findings, in addition to impaired consciousness upon arrival to 
emergency department, measured by GCS, and infratentorial hematoma location are 
the most important factors associated with increased early mortality, with hematoma 
volume being the most powerful individual predictor.10,73,76,109,110,271,273-286 Using 
National Institutes of Health Stroke Scale (NIHSS) score instead of GCS predicts 
mortality equally well.287 At simplest, the volume can be estimated on the initial CT 
by measuring the length, width, and depth of the hematoma and then dividing by 2.288 
OAC-associated ICH have been reported being irregularly shaped and using division 
of 3, therefore, predicts the volume more accurately.289 Higher volume of IVH also 
independently associates with poor outcome, as well as early growth of IVH (Figure 
9).290,291 Infratentorial ICH may damage brainstem, important brain structure where 
centers regulating many vital functions are located, if occurring in brainstem, or by 
pressure caused by transtentorial herniation, displacement of brain parenchyma 
behind tentorium. Cingulate herniation, resulting from large hemispheric ICH 
causing mass-effect, also predicts poor outcome.292 Higher age has also been reported 
to predict poor outcome in some studies.266,275-277 In 2001 Hemphill et al. presented 
a scoring system with these factors, the ICH score, to forecast patient’s odds for 
survival at 1 month.275 This, fairly easy-to-use tool for clinicians, has since been widely 
accepted, and also validated to prognose functional outcome at 6 months and 1 
year.266,293 Instead of admission, the score seems to be more accurate, when measured 
at 24 hours.294 Recently, a new scoring system for predicting outcome after IVH, 
the Modified Graeb Score, has been introduced, but not yet commonly accepted.295 
Midline-shift, lateral displacement of brain parenchyma, caused by mass-effect of 
hematoma or edema, also predicts increased mortality.266,292 IVH or hematoma may 
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also cause obstructive hydrocephalus by tempering with circulation of cerebrospinal 
fluid, another predictor of poor prognosis.279 Edema is not independently associated 
with outcome, but rather affects through large hematoma volume (Figure 9).89,93 
Investigators have recently reported a method to measure perihematomal edema 
with excellent reliability at baseline and 24 hours post-ICH.296 
Figure 9. A large ICH with IVH and severe brain edema.
OAC use associates with rapid clinical deterioration, as well as increased short-
term mortality, up to 67%, and poor functional outcome.71,143,144,146,147,187,224,227,228,297 
This results due to the larger hematoma volumes and hematoma expansion.298-303 
Preceding antiplatelet therapy also associates with increased mortality.136,304-306 High 
mean arterial blood pressure (MAP), hypothesized to be caused by “Cushing reflex” 
mechanism to maintain sufficient blood perfusion in the brain, but consequently 
causing ICP to increase, associates with early death and poor functional outcome, 
which may relate to higher hematoma volumes.307-311 Several other factors besides 
directly related to hematoma or pathological intracranial mechanisms have also 
been reported. Few studies have noted high plasma glucose on admission to 
associate with poor outcome, but the mechanism for this is unclear.11,312,313 The 
underlying etiology behind ICH may also contribute to the prognosis: ICH caused 
by hypertensive microangiopathy associates with poor outcome.109 Hypertensive 
ICH has been regarded different in clinical characteristics and outcome between 
the young and the elderly with the young having decreased mortality at the 
expense of more incapacitating disabilities suggesting age-related differences in 
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disease pathogenesis.314 This may be associated with subcortical hematoma location 
being also associated with poor outcome, since hypertensive ICH more often 
occurs in deep location. In addition, cardiovascular comorbidities associate with 
poor outcome: Ischemic heart disease and atrial fibrillation both associate with 
increased 3-month mortality after ICH.145,306,315-317 Diabetes and hypertension also 
emerge as factors predicting increased early mortality.284,312,318-320 Reasons for this 
remain yet unresolved, but increase in in-hospital complications has been proposed. 
On the contrary, pre-ICH statin use is not associated with increased mortality, 
poor functional outcome or higher hematoma volumes.124,321 Need of mechanical 
ventilation signals for poor outcome.322 Interestingly, preceding infections have also 
been identified to predict poor outcome in one study.323 Chronic kidney disease and 
renal failure have been identified to predict increased mortality and disability after 
ischemic stroke, as well as after ICH.173,324-338 Factors associated with poor outcome 
after ICH are summarized in Table 4.
Important finding is that early care limitations independently predict mortality.171 
Do-not-resuscitate order being associated with less active treatment and poor 
prognosis has been revealed by several studies.339-343 Clinicians should, therefore, 
avoid therapeutic nihilism and limiting treatment in the first few days that may 
cause self-fulfilling prophecies.344
Table 4. Summary of factors associated with poor outcome after intracerebral hemorrhage
Factor
Hematoma volume > 30 mL 266,275
Arrival GCS < 13 275
Presence and volume of IVH 275,290
Infratentorial hematoma location 275
Age > 80 275
Imminent herniation 292
Hydrocephalus 279
OAC use 297
Antiplatelet use 136,304-306
Hyperglycemia 11,312,313
Hypertension 109,318
Ischemic heart disease 315,316
Atrial fibrillation 315
Diabetes 284,312,318-320
Chronic kidney disease 173,324-338
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2.7.3  DIAGNOSIS AND INITIAL ASSESSMENT OF  
 INTRACEREBRAL HEMORRHAGE
Clinical evaluation alone is insufficient to differentiate ICH from other stroke 
subtypes, and to determine the characteristics and possible cause of ICH. Thus 
imaging of the brain is needed, and the diagnostic study of choice in ICH at first place 
is usually non-contrast brain computed tomography (CT). It provides a significant 
amount of information about the size and location of the hemorrhage, presence of 
intraventricular, subarachnoid, or subdural blood, and about the presence of mass-
effect with threatening herniation or hydrocephalus.279,292 CT differentiates ICH from 
cerebral infarction with high sensitivity – an imperative matter in the management 
of acute stroke, given the availability of thrombolytic therapy. Hemoglobin displays 
bright on non-contrast head CT.23 CT may also enable the prediction of hematoma 
expansion based on pattern of bleeding.
Magnetic resonance imaging (MRI) is as sensitive in detecting ICH as is CT, but 
superior in identifying perihematomal edema, arteriovenous malformation (AVM), 
amyloid angiopathy, or underlying neoplasm.345,346 MRI may provide important 
hints regarding underlying pathology, such as microbleeds, lacunar infarcts, and 
chronic white-matter change, which all suggest microangiopathy.120,121 It can also 
provide information about the time course of ICH.180 Compared to CT, shortcomings 
of MRI include longer scanning time, and limited possibilities to monitor and treat 
critically ill patient while in scanner. CT remains, therefore, as the gold standard, 
but MRI is the first-line imaging method for all younger ICH patients.200
Location of a hemorrhage may provide information about the etiology. Deep 
subcortical structures (putamen, caudate, thalamus), pons, cerebellum, and 
periventricular deep white matter are typical locations for hypertensive small-vessel 
disease, whereas single or multiple lobar hemorrhages in the cortical surface are 
often caused by CAA. These assumptions may, however, be incorrect: majority of 
patients with lobar ICH have a history of hypertension, and vascular malformations 
may also be the cause of deep or lobar hemorrhages.180,347 According to one study, 
in 48% of normotensive patients younger than 45 years, in 49% of patients with 
lobar hemorrhage, and 65% of cases with isolated intraventricular hemorrhage, 
there are abnormalities on angiography, such as aneurysm or AVM.144
CT-angiography (CTA), MR-angiography (MRA), or digital subtraction 
angiography (DSA) should be performed in all young patients due to the high 
likelihood of underlying vascular abnormality. Angiography should also be 
performed in other patients without obvious risk factors or cause of ICH, if 
intraventricular, subarachnoid, perisylvian, or interhemispheric fissural blood is 
present, if abnormal calcification or prominent draining vein is present, if hematoma 
shape is unusual (noncircular), if edema is out of proportion to the early time the ICH 
is first imaged, if location of ICH is unusual, and if abnormal structure in the brain 
is visible.9,348,349 Need of angiography also depends on whether patient is candidate 
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for neurosurgery, and angiography timing depends on urgency of surgery.180 If a 
suspicion of a structural abnormality remains after a negative CTA or MRA, an 
adjunct DSA is highly recommended after two to four weeks after the resolution 
of the hematoma, when vascular anomalies may become visible.47 In contrast to 
younger individuals, elderly patients with a history of hypertension and a thalamic, 
putaminal, or posterior fossa ICH are less likely to benefit from angiography.350 
Both contrast extravasation into the hematoma and presence of tiny enhancing 
foci, “spot sign” predict hematoma expansion and poor outcome.68,351-355 MRI with 
gadolinium as a contrast medium also gives insight to structural causes underlying 
ICH, such as a tumor. In general, an angiographic study is strongly recommended 
in ICH cases except in patients who are not candidates for active surgery or active 
treatment.
A detailed patient history and clinical examination are necessary in every ICH 
patient. A thorough examination should be conducted to detect signs of external 
trauma, pressure sores, and rhabdomyolysis, particularly in patients with depressed 
level of consciousness. A comprehensive laboratory evaluation covering a complete 
blood cell count, prothrombin time, activated partial thromboplastin time, serum 
electrolytes, liver function tests, glucose, glycosylated hemoglobin, C-reactive 
protein, creatinine, creatinine kinase, troponin-T, and coagulation profile, urea, 
nitrogen, and INR, is needed to detect underlying or complicating pathologies, such 
as infection, electrolyte disturbance, renal failure, rhabdomyolysis, or myocardial 
ischemia that are frequently treatable. Urine analysis, urine culture, and pregnancy 
test should be conducted in a woman of childbearing age, and toxicology screening 
should be executed in young and middle-aged patients to detect illicit drug use. 
Routine electrocardiography is also needed, for it may reveal prior cardiac injury 
indicating poor cardiac function, or left ventricular hypertrophy, an evidence of 
chronic hypertension, and chest radiograph, for it may reveal aspiration or other 
pulmonary process suffered, or an enlarged heart.23,180 
2.8 TREATMENT OF INTRACEREBRAL HEMORRHAGE
Acute treatment of ICH in intensive care stroke unit (ISCU) instead of general 
intensive care unit (ICU) or general ward has been consistently proved to reduce 
death and dependency, and is therefore strongly recommended.155,356-359 The reasons 
for this are most likely multifactorial, and include unified treatment strategies, 
dedicated multiprofessional teams familiar with the interactions between the 
injured brain and internal organ systems, and early access to stroke rehabilitation 
services.5,154,200 Substantial resources needed to treat patients with ICH include 
neurology, neurosurgery, neuroradiology, and critical care facilities. Medical 
complications, such as infections and venous thrombotic events are largely 
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preventable, and often serve as a measure of quality of standards in institutions with a 
stroke center designation.360 Having multiple complications strongly increase the risk 
of death.361 Combined treatment in ICSU and short-term ward with supported early 
discharge has been proposed to reduce mortality and complications in comparison 
to general medical ward.362 Unfortunately, some patients require being transferred 
back to the primary referring physician.363,364 A pro-active approach in order to 
prevent, identify, and treat any complications early in all stroke patients to improve 
outcome and reduce costs, therefore, is imperative.363,365,366
2.8.1 PREHOSPITAL MANAGEMENT
ICH is a medical emergency and therefore any delays in treatment may result in worse 
outcomes. Initial prehospital care should focus on ventilatory and cardiovascular 
management by maintaining airways, breathing, and circulation to prevent hypoxia 
and limit hematoma growth while maintaining cerebral perfusion.200 Quick delivery 
to the nearest emergency department (ED) is imperative in patients with abrupt 
neurological focal deficit, such as hemiparesis, impaired consciousness, or severe 
headache, which is presumed to be of vascular origin until proven otherwise.9,180 
Finally, an advance notice to the ED of the forthcoming potential stroke patient by 
emergency medical service providers is of great value, since it shortens the time 
to CT in the ED.367
2.8.2 INITIAL MANAGEMENT IN THE EMERGENCY DEPARTMENT
It is of utmost importance that ED is prepared to treat patients with ICH or has 
a plan for swift transfer to a tertiary center.9 Majority of ICH patients are instable 
in the acute phase and require close monitoring, particularly on cardiovascular, 
respiratory, and neurologic status. Respiratory and hemodynamics may be 
compromised in patients with impaired consciousness. Cardiovascular instability 
associated with increased ICP needs immediate attention to avoid the damage 
caused by hypertension or hypotension in a patient with limited autoregulation.47 
Initial management should focus on stabilization of cardiorespiratory function and 
treatment of intracranial complications. Intubation is needed, if other measures 
are insufficient to protect airways and sustain adequate ventilation in patients with 
decreasing consciousness (GCS≤8) or impairment of reflexes protecting the airways. 
Approximately 30% of patients with supratentorial ICH and majority of patients 
with infratentorial ICH require intubation.322 Low GCS has been identified as a factor 
predicting a need for tracheostomy in two studies.368,369 One of them also described 
hydrocephalus, midline-shift, thalamic location of hematoma, large hematoma 
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volume, and intraventricular hemorrhage factors to associate with tracheostomy.368 
Initiation of tracheostomy early could reduce the length of stay in hospital.369 Elective 
tracheostomy should be performed after intubation of 2 weeks at the latest. 
Urgent brain CT scanning upon arrival to the ED is vital to differentiate between 
ischemic stroke, subarachnoid hemorrhage, and intracerebral hemorrhage, and to 
evaluate the characteristics of hemorrhage, such as location and volume, as well as 
to detect presence of IVH, edema, increased ICP, obstructive hydrocephalus, and 
imminent brain herniation.
2.8.3 REVERSAL OF ANTICOAGULATION
Effects of vitamin K antagonists must be reversed in the ED.200,370-374 Due to the lack 
of data on RCTs investigating OAC reversal on ICH patients no uniform guidelines 
to treat these patients currently exist, but clinical observational and pharmacological 
data have led to infusion of vitamin K and fresh frozen plasma (FFP) for patients on 
vitamin K antagonists and intravenous protamine sulfate for patients on heparin, 
until INR of 1.2 has been reached.154,155,375-377 Vitamin K has a long-lasting effect by 
promoting endogenous clotting factor synthesis, but as it takes 6 hours to take effect, 
immediate use of fresh frozen plasma (FFP) or prothrombin complex concentrate 
(PCC) should as well be executed for vitamin K antagonist reversal. FFP contains 
factors II, VII, IX and X. It has short duration of action, and therefore large volumes 
may be required. If the patient’s cardiac reserve or intracranial compliance is limited, 
a sufficient amount of FFP cannot be given fast enough due to the risk of heart 
failure or increased ICP.373,376 FFP also has the general risks and disadvantages of 
blood transfusion.
PCCs are plasma products containing high concentrations of factors II, IX, and 
X, with or without factor VII.378-381 PCC can correct INR faster than FFP, and more 
effectively reduce hematoma growth, as well as to improve outcome in observational 
studies.71,301,382 Although dose related, PCCs are also associated with higher risk 
of thromboembolic complications than FFP.383 Recombinant factor VIIa is a new 
candidate for rapid reversal of vitamin K antagonist anticoagulation, but further 
randomized trials are needed to support its use in this indication.384-388 According to 
the recommendations of AHA and ESO, anticoagulation can be resumed between 
7 and 14 days after the ICH in patients with high risk for thrombotic events (e.g. 
in patients with prosthetic valve).152,158,374,389-391
No specific antidote yet exists for novel oral anticoagulants (apixaban, dabigatran, 
edoxaban, rivaroxaban), nor has there been RCTs investigating the treatment of ICH 
associated with them. Antidotes are expected to be available in the near future. Our 
knowledge regarding the treatment of ICH caused by thrombolytic therapy is limited 
also, but PCC, antifibrinolytics, cryoprecipitate, FFP, Vitamin K, aminocaproic acid 
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and platelets have been used.235,392 Antidotes are under development and currently 
some are already under investigation in clinical trials.
2.8.4 HEMOSTATIC TREATMENT
Halting the ongoing bleeding and hematoma expansion is crucial and should 
improve the outcome. Recombinant factor VIIa (rFVIIa) was originally developed 
as a treatment for hemophilic patients, and has since been investigated as a 
treatment to control bleeding in major trauma and surgical catastrophies.393 It was, 
therefore, proposed and later confirmed that early hemostatic therapy with rFVIIa 
prevents further hematoma expansion in patients with ICH.64,66,394,395 Freeman et al. 
demonstrated that rFVIIa rapidly lowers INR and appears safe to use in patients 
with OAC-associated ICH.396 Mayer et al. published promising results from a phase 
II trial, in which 399 patients with spontaneous ICH were randomized to receive 
placebo or 1 of 3 doses of rFVIIa within 3 hours after ictus. Those who received 
rFVIIa had less hematoma expansion, less edema, and smaller lesion total volume, 
in addition to 38% relative reduction in mortality and a dose-related trend toward 
less morbidity.6,66 Unfortunately, when rFVIIa was tested in a phase III trial (the 
FAST-trial) involving 821 patients from 22 countries with spontaneous ICH without 
coagulopathy, the treated group had less hematoma growth and improved outcome 
at 15 days, but the mortality and disability at 90 days were indifferent.397 Those 
treated had adversely more thrombotic events, such as myocardial infarction and 
cerebral infarction, which most likely resulted in increased mortality and morbidity 
at 90 days. RFVIIa also increases risk for deep vein thrombosis, a complication 
of ICH, associated with hospitalization and immobility.398 A fairly recent meta-
analysis confirmed these findings.399 Routine use of rFVIIa, therefore, is not currently 
recommended for treatment of ICH.155,200 A post-hoc analysis of data from FAST-
trial suggested that those under 70 years of age with hematoma volume less than 
60ml might benefit from rFVIIa administered within 2.5 hours from symptom 
onset. More data are needed to confirm this, and to identify other patient subgroups 
which would benefit from rFVIIa. Efficacy of tranexamic acid for treatment for ICH 
is also being investigated by RCTs currently.
Platelet transfusion has been proposed for treatment of ICH in those 
receiving antiplatelet drugs.400-402 Replacing the non-functional thrombocytes 
with functional ones might increase the chance of hemostasis. Only one study, 
however, has so far investigated the use of thrombocytes for ICH, and the patient 
sample was rather small.403 In this study, platelet transfusion had no effect on 
platelet function or ICH progression. Two RCTs investigating platelet transfusion 
for ICH are currently ongoing.
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2.8.5  MANAGEMENT OF INCREASED INTRACRANIAL PRESSURE  
 AND BRAIN EDEMA
Increased ICP may result after mass-effect caused by hematoma or surrounding 
edema, inflammation and destruction process caused by bleeding, or obstructive 
hydrocephalus from IVH or hematoma pressing CSF circulation system.404-407 Our 
knowledge regarding the frequency and optimal management of increased ICP in 
patients with ICH is, however, limited due to the lack of data.9,404,406 It is considered 
to be a major contributor to mortality and poor functional outcome after ICH, 
and detection and treatment of it, thus, is essential.405,408 ICP monitoring should 
be considered for all patients with large hemorrhage, IVH, GCS score of 8 or less, 
those patients whose condition is thought to be deteriorating due to elevated ICP, 
and those who need to be sedated or pharmacologically restrained and that way 
have compromised clinical monitoring, those with external ventricular drainage 
(EVD), and, obviously, those who are treated for increased ICP.9 Patients with 
small hematomas and limited IVH usually do not require treatment to lower ICP. 
According to one study preoperative monitoring of ICP associated with delayed 
neurological deterioration, decreased early mortality, and improved functional 
outcome at discharge, but no association was found with 6-month outcome.409
Treatment of increased ICP should be directed at the underlying cause, 
particularly if caused by hydrocephalus or mass effect from the hematoma (see 
later section regarding these).154,404,405,410,411 We are still lacking evidence from RCTs 
to make strong recommendations on measures to lower ICP in adults with ICH.155,407 
Hyperventilation is commonly used to treat ICP. In case of impending transtentorial 
herniation, a combination of hyperventilation and osmotherapy is frequently used, 
though data from RCTs is lacking.412
Osmotherapy is the first-line medical treatment for increased ICP by reduction 
of perihematomal edema. It has been proved promising in animal models, and two 
nonrandomized clinical trials.412-417 Mannitol can be used, for it is believed to extract 
water from the cerebral extracellular space of both normal and edematous brain into 
the intravascular compartment. It should not be, however, used prophylactically or 
more than five days..180 Glycerol has been tested in one RCT on 107 ICH patients 
over four hours for six consecutive days, but no differences emerged at 6-month 
mortality or disability in comparison to placebo.418
Neuromuscular paralysis combined with adequate sedation, as well as optimal 
head positioning can reduce elevated ICP.180 General anesthesia by barbiturares and 
induced hypothermia should only be used if other methods are ineffective.419-422 Pilot 
data indicated mild hypothermia (35°C) started within 12 hours from onset for 10 
days reduced perihematomal edema and resulted in relatively high survival and 
functional outcome at 12 months.422 Several studies have investigated corticosteroid 
treatment in patients with ICH.423-429 A recent meta-analysis of these studies found 
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no beneficial effect of dexamethasone on 6-month case fatality.155 Corticosteroids 
are, therefore, not currently recommended for treatment of ICH.155
2.8.6  TREATMENT OF INTRAVENTRICULAR HEMORRHAGE  
 AND HYDROCEPHALUS
If ICH extends near to ventricles, i.e. originating from basal ganglia or being lobar 
with large volume, it may spread to CSF circulation (IVH).291,430 It has been reported 
being present among 40% to 60% of all ICH patients, but, interestingly, among 
only 3% to 4% of young patients.109,110,266,290,291,404,431-435 Delayed IVH seems to be less 
common and more benign than one discovered on admission.436 
The adverse effect may be related to IVH interfering with normal functions of 
CSF by causing localized lactic acidosis, and causing mass-effect on periventricular 
structures, which is associated with global hypoperfusion of overlying cortex.47,290,437 
IVH blood clot may also cause obstruction of the CSF flow resulting in obstructive 
hydrocephalus, and even subsequent herniation, another predictor of poor outcome 
after ICH, usually manifesting with unconsciousness (Figure 10).279,291,404,405,434-
436,438-442 In addition, it may cause inflammation of the choroid plexus leading to 
increased CSF production and that way worsening hydrocephalus, as well as cerebral 
vasospasm.439 Delayed communicating hydrocephalus may also follow IVH, when 
the degradation products of the blood clot generate an inflammatory response that 
gradually occludes the arachnoid granulations where CSF is absorbed.434 
Figure 10. ICH and IVH causing obstructive hydrocephalus.
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Hydrocephalus (Figure 10) is a life-threatening condition, and should be treated 
with EVD of CSF through an intraventricular catheter, as an emergency measure, 
if necessary.404,405,434,435,441,442 EVD reduces ICP, but also carries a risk of clotting 
and infection.430,443,444 Intrathecal thrombolysis with urokinase is used to prevent 
and treat hydrocephalus, since it has been reported to reduce mortality and 
it seems acceptably safe.291,404,430,444-451 In accordance, a recent meta-analysis 
concluded intraventricular fibrinolysis being safe, and possibly reducing mortality, 
improving functional outcome, and diminishing the need for permanent shunting 
without increasing the risk of infection or rebleeding.452 The Clot Lysis: Evaluating 
Accelerated Resolution of Intraventricular Hemorrhage (CLEAR) III RCT is still 
ongoing. Dutch Intraventricular Thrombolysis after Cerebral Hemorrhage study 
(DITCH) is also ongoing. ESO guidelines currently recommend considering the use 
of EVD combined with fibrinolytic agent in patients with spontaneous ICH with IVH 
and clinical and/or neuroradiological signs of hydrocephalus.155 Neuroendoscopic 
removal of blood clot in IVH has shown promising results, but no conclusive 
evidence yet exists regarding the preference between that and EVD.453-456 Too 
few data also exist to support open surgical evacuation, or lumbar drainage of 
IVH.434,448,457 Clot-removal techniques may improve in the future, as our knowledge 
on pathophysiological mechanisms associated with clot progression ameliorates, 
and minimally invasive surgical methods combined with atraumatic catheter-based 
clot removal are developed.430,458,459
2.8.7 NEUROSURGICAL TREATMENT
Controversy has dominated the debate of neurosurgical evacuation of hematoma 
from the brain parenchyma, and the feasibility of surgical intervention still remains 
unanswered.460-471 Only with infratentorial hematomas, due to the risk of obstructive 
hydrocephalus, brainstem compression, and neurological deterioration, advantage 
of immediate surgical evacuation over EVD alone, particularly if ICH width is >3 
cm, has been approved.154,472-477 Although reported evidence includes only few patient 
samples, a RCT to test this now would be unethical.
A meta-analysis of seven trials failed to show clear benefit of surgery for ICH.461 
The results from the International Surgical Trial in Intracerebral Hemorrhage 
(STICH), showed no overall benefit or disadvantage from early surgery over 
initial conservative treatment.433 A post-hoc analysis of the STICH trial showed 
that patients with superficial hematomas and IVH absent benefit from surgery.438 
A Cochrane review from 2008 including ten RCTs with 2059 patients concluded 
that surgical evacuation added to best medical management reduces mortality and 
disability.478,479 A meta-analysis on 12 studies published one year before that reported 
similar results.480 Later on, STICH II investigated whether surgical evacuation would 
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reduce mortality or disability at 6 months in patients with lobar ICH without IVH. 
The results, unfortunately, did not show significant difference in this RCT either.432 
No significant benefit for survival or functional outcome was also reported by 
another recent study including ICH in other locations besides lobar ones.481 As 
a rule, young and middle-aged patients have been excluded from all these RCTs, 
as well as those with imminent herniation, and therefore recommendations for 
these patients remain uncertain.154 The role of decompressive hemicraniectomy in 
treatment of ICH is not established. 482 Another unanswered issue is the optimal 
timing for surgery. 433,483-489 
Minimally invasive surgery (MIS) is another option and offers some advantages 
over conventional craniotomy, including the possibility for local anesthesia, reduced 
operating time, and reduced tissue trauma.5,200,470 Studies on endoscopic clot 
evacuation have reported decreased mortality, but results concerning functional 
outcome have been contradictory.486,490,491 Stereotactic aspiration and thrombolysis 
of hematoma by image guidance is the second main type of MIS.489-498 Preliminary 
results from “Minimally Invasive Surgery Thrombolysis Plus Recombinant Tissue-
type Plasminogen Activator for ICH Evacuation” (MISTIE) and results from 
“Stereotactic treatment of intracerebral hematoma by means of plasminogen 
activator” (SICHPA), showed greater clot resolution and decreased perihematomal 
edema with MIS and rtPA than with traditional medical management.485,499,500 
According to a recent meta-analysis of 12 RCTs with 1955 patients, those with 
supratentorial ICH may benefit from MIS in comparison to conservative medical 
treatment and conventional craniotomy, particularly those of age between 30 and 
80, those with superficial hematoma, GCS score ≥9, hematoma volume between 25 
and 40 mL, and intervention performed within 72 hours after onset of symptoms.501 
These findings are supported by another recent meta-analysis comparing stereotactic 
aspiration and craniotomy.502
According to AHA guidelines, last released in 2010, before above-mentioned 
meta-analyses, the effectiveness of minimally invasive clot evacuation utilizing 
either endoscopic or stereotactic aspiration with or without thrombolytic usage 
is uncertain due to greatly depending on the accurate catheter placement and, 
therefore, considered investigational.154 The MISTICH and ICES trials are RCTs 
currently in progress to define whether MIS could improve the prognosis of ICH in 
comparison to craniotomy, and ECMOH is a RCT investigating whether endoscopic 
surgery is better than conservative treatment for patients with moderate-volume 
hematomas in the basal ganglia.503,504
Surgical intervention may be needed in case the underlying etiology of ICH is 
structural, such as AVM or cavernous hemangioma, visualized by CT angiography 
or MRI. Ruptured AVMs can be treated with microsurgery, endovascular treatment, 
stereotactic irradiation, or by observation with medical management, according to 
the commonly accepted Spetzler-Martin classification.505-511 The optimal strategy for 
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management is still under debate. With hemorrhagic cavernomas, microsurgery 
has been declared as the only healing therapy.512-515
Current practice favors surgical intervention in case of ICH being superficial, 
clot volume being between 20 and 80 ml, worsening neurological status, patient 
being of young age, and if ICH is causing midline shift or increased ICP. Opposing 
factors include hematoma being small (<2 cm) in an alert patient, and hematoma 
being extensive in a moribund patient, often causing coma with poor motor 
responses and unreactive pupils.466 Individualized decisions account also age, 
site of hematoma, underlying etiology and the presence of accompanying 
systemic complications.466 Brainstem or thalamic hemorrhages are usually not 
evacuated, due to the poor consequences.180 While the decision to operate a 
supratentorial ICH is currently based on local traditions, the need for clear and 
strong international guidelines is obvious.
2.8.8 BLOOD PRESSURE MANAGEMENT
High BP commonly occurs with ICH and usually persists for few days before returning 
to baseline.23 At presentation, 75% of ICH patients have systolic blood pressure (BP) 
>140 mmHg, and 20% have >180 mmHg.259 High BP is caused by the activation 
of a combination of neuroendocrine system (catecholamines), renin-angiotensin 
axis, and glucocorticoid system involved in a nonspecific response to stress, and 
further worsened by the patients’ chronic hypertension.9,309,516 Brainstem-mediated 
release of catecholamines may be induced by increased ICP. This hypothesized 
“Cushing reflex” is a protective response aiming to preserve cerebral perfusion.516 
However, high BP on admission is associated with hematoma expansion and poor 
outcome.64,68,69,517-523 It may also worsen cerebral edema. The rationale for lowering 
BP, therefore, is to decrease ongoing bleeding and reduce hematoma expansion. It 
has been suggested that overaggressive treatment of BP may, however, decrease CPP 
and worsen brain injury, particularly if increased ICP is present, for it may hamper 
autoregulation.524,525 The absence of ischemic penumbra around a small-volume 
ICH means that sudden therapeutic reduction of BP does not necessarily involve 
the same risks that are well known with ischemic stroke. Studies on autoregulation, 
cerebral perfusion, and one randomized study showed no significant reduction in 
cerebral blood flow if the pressure is lowered 20% or less in the acute phase.6,526-528 
One observational study reported better outcomes in ICH patients whose BP 
was maintained below mean arterial pressure (MAP) of 125 mmHg.308 Another 
observational study reported hematoma expansion in 9% of patients when systolic 
BP was maintained <150 mmHg, and 30% of patients with BP maintained <160 
mmHg or a higher threshold.523 Two pilot RCTs and one large RCT have investigated 
BP management on outcome after ICH.65,529-531 The investigators from ATACH study 
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and INTERACT study both reported early BP-lowering treatment being clinically 
feasible and well tolerated. Results also inferred it may reduce hematoma growth.65,531 
These results were only recently confirmed in a large RCT (INTERACT2) concluding 
that intensive lowering of BP, with a target systolic level of <140 mmHg within 1 
hour did not increase mortality.530 Unfortunately, treatment of BP did not either 
reduce mortality or severe disability at 90 days, but indicated improved functional 
outcomes. Candesartan at one to seven days following stroke did not improve 
outcome after ischemic stroke or ICH.532 More evidence is needed regarding the 
utility of hyperacute BP reduction after ICH, and therefore ATACH-2, ENOS, and 
PATICH are RCTs currently investigating BP treatment on ICH.533
In 2014 updated guidelines based on meta-analysis of RCTs ESO concludes 
that intensive BP reduction with target systolic BP <140 mmHg is safe and may 
be superior to a target of < 180 mmHg.155 The AHA guidelines state that the 
management of hypertension with continuous infusion of antihypertensive drugs 
such as labetalol, esmolol, or nicarpidine, should be aggressive if systolic blood 
pressure (SBP) is >200 mmHg or mean arterial blood pressure (MAP) is >150 
mmHg and modest if SBP is >180 mmHg or MAP is >130 mmHg and there is no 
evidence or suspicion of increased ICP, in which case the goal is 160/90 mmHg and 
MAP 110 mmHg. While using intravenous medication to control BP, patient should 
be re-examined every 15 minutes.9,154 The optimal timing of conversion from IV to 
oral antihypertensive therapy is unclear, but it is usually recommended between 
24 to 72 hours with stable patients.
2.8.9 PREVENTION AND MANAGEMENT OF SEIZURES
Post-stroke seizure and post-stroke epilepsy may occur as the presenting 
symptom or complication of hemorrhagic or ischemic stroke. Early seizures are 
more common in patients with ICH in comparison to other stroke subtypes, and it 
also associates with lobar lesion location.534-537 Clinical seizures occur in 2.7 to 25% 
of patients with ICH, with most of them occurring near ICH onset.537-547 Seizure 
occurring more than 2 weeks after ICH onset is higher risk for recurrent seizure 
than one occurring within 2 weeks, and long-term prophylactic anticonvulsant 
treatment may be needed.442 Chronic epilepsy develops in 13% of 30-day to 2-year 
survivors and in 7% of the 2- to 5-year survivors.537 Electrographic seizures have 
been reported to occur in 28 to 31%, despite most having received prophylactic 
anticonvulsants.548,549 The clinical impact of those subclinical seizures detected 
only in EEG is uncertain. Seizures occurring within one week after ictus are 
defined as early seizures, and a rate of 14% of early seizures has been reported 
after ICH.536,550 One RCT investigated the adverse effects of diazepam.551 These 
investigators reported diazepam being associated with increased pneumonia and 
41
death. Investigators from another RCT found that patients receiving valproic 
acid were less likely to suffer from early seizures, but overall seizure rates by 
one-year follow-up did not differ.552 While early seizures are not associated with 
worsened neurological outcome or mortality at short- or long-term follow-up, 
phenytoin use and prophylactic antiepileptic drug (AED) use have been reported 
to associate with worse outcome after ICH.536,547,550,553-556 In one large single-center 
study prophylactic AED use significantly reduced clinical seizures in patients 
with lobar ICH.557 AHA guidelines state that only patients with clinical seizures 
or electrographic seizures accompanied by change in mental status should be 
treated with AED. Patients with depressed mental status out of proportion to 
the degree of brain injury should be monitored by continuous EEG. Both AHA 
and ESO guidelines state, that due to the lack of RCTs, utility and optimal use 
of AED remains unresolved.154,155 Intravenous lorazepam in usually the first-line 
drug for acute management of seizure, and AED treatment should follow the 
local hospital guidelines.
2.8.10 GLYCEMIC CONTROL
Hyperglycemia is common after ICH and associates with increased ICU and 
hospital length of stay and worsened outcome.17,558 Hyperglycemia is considered 
deleterious to damaged brain, but the exact underlying mechanisms are yet to 
be resolved.312,313,559,560 Often present among patients with ischemic stroke, it is 
associated with poor outcome, and recommended by AHA and ESO guidelines to 
be treated with intravenous insulin.561-563 Hyperglycemia has been reported to worsen 
the outcome after ICH also with or without diabetes.312,313,564,565 High blood glucose 
level has been associated with more profound brain edema and perihematomal 
cell death in experimental ICH, but the slight retrospective evidence did not 
support this, nor was it associated with hematoma expansion.313,566 Excessive use 
of insulin among patients with ischemic stroke or ICH may result in hypoglycemia 
with reduced cerebral extracellular glucose concentration, which also causes 
increased mortality.567-575 Rapid decrease in serum glucose level also decreases 
serum osmolality and may theoretically worsen cerebral edema. Some guidelines 
recommend lowering glucose levels if exceeding 10.0 mmol/L (180 mg/dl) with 
avoiding hypoglycemia and large swings in blood glucose concentration.5,200 Glucose-
containing fluids should be avoided in ICH patients unless they are hypoglycemic. 
Other systemic medical complications, such as infections and fever, may also cause 
hyperglycemia, and should be treated accordingly. No uniform guidelines yet exist 
for the treatment of ICH-associated hyperglycemia and the optimal criteria, target 
levels, and method of treatment of hyperglycemia are not solidly defined.
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2.8.11 FLUID MANAGEMENT AND ELECTROLYTE IMBALANCE
Electrolyte disturbances may arise after brain injury due to the major role of 
the central nervous system on controlling sodium, potassium, chloride, calcium, 
magnesium, and water homeostasis (CSWS, Cerebral Salt Wasting Syndrome), 
dehydration, as well as cardiac failure.325,576-580 Hypo- and hypervolemia both have 
harmful effects on cerebral perfusion and functioning of other organs. Establishing 
and maintaining normovolemia is, therefore, the main goal of fluid management 
in acute ICH.
A 15.6% prevalence of hyponatremia among ICH patients has been reported and 
it has been identified as a predictor of in-hospital mortality in two recent studies.338,581 
Hypernatremia resulted in 57% one-month mortality among ischemic and 
hemorrhagic stroke.325 Interestingly, the latter investigators reported hyponatremia 
and hypernatremia being associated with cortical lesion instead of basal ganglia 
or infratentorial lesion with ischemic stroke, but hypernatremia being associated 
with brain stem lesion with ICH.325 Data on other electrolyte disturbances and their 
effect on ICH prognosis are still very limited, but sodium and potassium imbalance 
have been reported to associate with worse outcomes after ischemic stroke.582,583 
Rapid increase of natrium concentration may cause fatal pontine myelinolysis, while 
potassium disturbances may cause cardiac arrhythmias.584
Isotonic infusion of intravenous fluids without glucose should be used in 
general to maintain adequate intravascular volume to optimize cerebral perfusion. 
Hypotonic solutions are contraindicated, because of the risk of increase of 
brain edema as a consequence of reduced plasma osmolality, and high glucose 
concentration has detrimental effects on injured brain. Electrolyte disturbances 
should be investigated and corrected according to the severity, suspected duration, 
and cause. Severe hyperpotassemia may require temporary intravenous glucose 
and insulin treatment.584
2.8.12 CONTROLING BODY TEMPERATURE
Central fever and infections may complicate ICH, and fever is an independent 
predictor of poor outcome in these patients.585-587 Body temperature should be, 
therefore, maintained at normal to near-normal levels. Acetaminophen or cooling 
blankets can be used to treat hyperthermia >38.5°C.180,588 Catheter-based cooling 
techniques have been tested in two RCTs, but the number of ICH patients has 
been too small to evaluate their effect on clinical outcome.589,590 These may be 
used with persistent fever refractory to acetaminophen and without infectious 
cause.14 Some patients might even benefit from hypothermia, which acts as anti-
inflammatory cytokine, reduces oxidative stress, and has been reported to improve 
the outcome.420-422,591-597 Our knowledge on hypothermia for ICH, however, is still 
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minimal, and guidelines recommend targeting normothermia.598 Due to the lack of 
RCTs, no strong recommendations are currently available for optimal treatment of 
fever in patients with ICH.155 Early treatment with antipyretics may be considered 
in clinical practice, but preventive treatment is not recommended.155 Appropriate 
cultures and smears (tracheal, blood, urine, CSF) should be obtained, and patient 
physically examined to determine the source of infection in febrile patients and in 
those at risk for infection, as well as appropriate antibiotics initiated.
2.8.13 VENOUS THROMBOEMBOLISM PROPHYLAXIS AND TREATMENT
In the acute phase of ICH, patients are most often immobilized due to neurological 
deficit or impaired consciousness, putting them at risk for deep vein thrombosis 
(DVT), and subsequently for pulmonary embolism (PE). Without any preventative 
measures DVT develops in up to 50% of ICH patients.599-605 Women and those of 
African American ethnicity are in higher risk for DVT.103,606-608 Measuring D-dimer 
after 2 weeks from ICH may be useful to detect DVT.600,609 As many as 30% of patients 
with pulmonary embolism show no evidence of lower extremity DVT.602,610 Thigh-
high or below-knee elastic stockings, intermittent pneumatic compression (IPC), 
and anticoagulation by subcutaneous low-molecular-weight heparin (LMWH) and 
unfractionated heparin have been investigated in multiple RCTs for DVT prevention 
after ICH.601-603,611-620 Elastic stockings alone are ineffective, while IPC has been 
proved superior in comparison to other methods and is currently recommended 
by AHA and ESO both to improve outcome and reduce the risk of DVT in immobile 
patients with ICH.154,155 LMWH seems to be safe initiated on the second day after 
ICH onset in neurologically stable patients, but may not be more effective than 
elastic stockings.611-613,618,620 IPC and elastic stockings are rational choices particularly 
in patients with ongoing bleeding demonstrated by hematoma expansion. Inferior 
vena cava filters or 5 to 10-day course of full-dose LMWH followed by 3-months 
of low-dose LMWH is preferable than vitamin K antagonist for DVT treatment.621 
2.8.14 INFECTION COMPLICATIONS
Stroke induces systemic immunosuppression by cellular pathways.622-626 Infections 
are frequently complicating the early course and recovery from stroke, and seem to 
be more often present in patients with ICH than those with ischemic stroke.17,624,627-629 
A meta-analysis of 87 studies involving 137817 patients investigated infections and 
other complications among stroke patients.323,361-366,628,630-648 The key message of these 
studies is that infections are common, most often include pneumonia and urinary 
tract infection (UTI), and associate with higher mortality, worse functional outcome, 
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and increased hospital length of stay. Same findings were reported in a recent study 
focusing on infections among ICH patients.649 Stroke severity is the most substantial 
factor that increases risk for all complications, including infections.633,637,638,640-643 
In addition to cellular and biochemical mechanisms of immunosuppression 
induced by ICH, dysphagia, mechanical ventilation, tracheostomy, and tube 
feeding have also been reported to increase risk for pneumonia.650-652 Impaired 
consciousness is the single most important risk factor for pneumonia. Dysphagia 
is a frequent symptom of ischemic and hemorrhagic stroke both, being present in 
up to 50% of stroke patients, and may cause bronchoaspiration with subsequent 
pneumonia.653 Pneumonia develops in 14% to 20% of all ICH patients, and associates 
with increased morbidity, mortality, and length of stay.338,610,650-652,654,655 Pneumonia 
plays an important role, since it increases risk for other complications among ICH 
patients, such as gastrointestinal bleeding, decubitus ulcer, DVT, atrial fibrillation, 
and recurrent stroke.632
UTI complicates the course of ICH in up to 21% of patients.654 Stroke-induced 
immunosuppression, bladder dysfunction, use of Foley urinary catheter, and female 
gender predispose for UTI.641,656 Even without a catheter, stroke patients have more 
than double the odds of developing UTI in comparison to general medical and 
surgical populations.657 UTI alone predicts poor outcome, but may also progress 
into sepsis with fever, and cause delirium, even stronger predictors of increased 
mortality.586,654,658-660 Several strategies have been proposed to reduce UTI after 
stroke. Prophylactic use of antibiotics has been studied in few RCTs, but due to 
contradictory findings, and questions regarding the risk of selecting resistant 
organisms, feasibility of prophylaxis has remained unanswered.656,661-663 Unnecessary 
use of Foley catheters should be avoided. New strategies such as condom catheters 
and antiseptic/antibiotic-covered catheters are under development.
2.8.15 CARDIAC COMPLICATIONS
Cardiorespiratory instability usually occurs within 24 hours following ICH onset.47,358 
Knowledge regarding occurrence, impact, and underlying mechanisms of cardiac 
complications after ICH, as well as strategies to prevent them is still limited. 
Severe in-hospital cardiac events include myocardial infarction (MI), heart failure, 
ventricular arrhythmias, and sudden death due to cardiac arrest.629 They likely result 
from brain injury causing disturbance in central autonomic control. Post-stroke 
cardiac complications result in higher mortality, need for intensive monitoring, 
and increased length of stay with higher costs.664-668 Between 2% to 6% of patients 
die from a cardiac cause within three months after ischemic stroke, and up to 19% 
suffer a serious cardiac adverse event.365,646,668-672 MI has been reported occurring in 
2% within 3 months after ICH.606 In-hospital occurrence of MI after ischemic stroke 
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or ICH has been reported being between 1% and 5%.637,648,665,667,673 Potentially lethal 
arrhythmias in telemetric monitoring was seen among 1% in patients with ischemic 
stroke in one study, but another study reported up 25% of patients with acute 
cerebrovascular event having significant cardiac arrhythmias.358,674 Arrhythmias 
may precede or be caused by heart failure, which may further lead to neurogenic 
pulmonary edema.675-681
Cardiovascular comorbidities, higher age and stroke severity have been identified 
to increase the risk of cardiac morbidity and mortality after stroke.358,665,667,668,682 
Troponin elevation, atrial fibrillation, and ischemic ECG changes may be associated 
with higher in-hospital mortality.674,683-686 Both troponin T elevation and ECG 
changes, however, are frequent after stroke, and most often are unrelated to acute 
myocardial ischemia.637,687,688 Elevated troponin I independently associates with 
higher in-hospital mortality and cardiac causes of death after ICH, but is present 
only in 1% of ICH patients.689 
Takotsubo cardiomyopathy is a phenomenon caused by stress, in which sudden 
reversible weakening of left ventricle occurs.690-701 ICH may provoke Takotsubo 
cardiomyopathy, but the rates have not been investigated. It has been reported to 
occur in 1% of patients with ischemic stroke, with most occurring during 10 hours 
after onset, but some even after 12 days, and female gender and insular damage being 
risk factors.696 It may cause heart failure, ventricular arrhythmias, and ventricular 
rupture, all potentially lethal, particularly in vulnerable ICH patients.702
Most sudden deaths and serious non-fatal cardiac events after stroke are probably 
due to interactions between cardiovascular and neurological causes that are not 
yet fully understood. Telemetric monitoring and readiness for cardiorespiratory 
support are, therefore, vital after stroke.674
2.8.16 RENAL FAILURE
More evidence exists on renal failure being associated with poor outcome after 
ischemic stroke, but only few studies have investigated renal failure among ICH 
patients.330,333-335 Chronic kidney disease has been reported in as many as one third of 
ICH patients, and acute renal failure in 7%, more often among women, elderly, and 
those with other comorbidities, such as diabetes.330,333 Chronic kidney disease and 
renal failure seem to increase mortality by kidney function: the lower the glomerular 
filtration rate (GFR) is, the higher the mortality rates are.330,333-335 The proportions 
of renal failure preceding and appearing during acute ICH, the pathophysiological 
mechanisms by which ICH affects kidney function, and the strategies of prevention 
and treatment to address this issue and improve outcome remain unresolved.
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2.8.17 NEUROPROTECTION
Neuroprotective strategies to reduce secondary brain injury after ICH, caused 
by oxidative stress, inflammation, and blood degradation, has been investigated 
in animal studies, including iron chelation by deferoxamine, heme oxygenase 
inhibition, blocking inflammatory pathways, inhibition of toxic neurotransmitters, 
antioxidants, matrix metalloproteinase inhibition, and antiapoptotic strategies. The 
impact of microglia and macrophages in hematoma resolution is being investigated. 
Autophagy may be a cellular process that could be targeted to prevent apoptosis.154 
So far, only rosuvastatin has shown beneficial effects, but further studies are 
ongoing.200,703-711 
2.8.18 OTHER MEDICAL MANAGEMENT
ICH patients are at risk of stress-induced gastric ulcers, which has been reported 
to develop in approximately 20% of these patients. Prophylactic treatment with H2 
receptor antagonists or proton pump inhibitors is, therefore, indicated. No uniform 
guidelines based on RCTs addressing prevention of gastric hemorrhages on ICH 
patients yet exist. ICH may also cause delirium, stupor, disorientation, and agitation, 
which may further result in hyperactivity – distressing to other patients, caregivers, 
and family, and may lead to self-injury. Psychological support is paramount, but 
prudent use of minor and major tranquilizers, such as short-acting benzodiazepines 
or propofol may be necessary for some patients. Analgesics and neuroleptics may 
be added, if needed. Titration of doses and regimen according to clinical needs is 
of primary importance.23,180,442 Body posture in bedridden patients must be altered 
and skin checked for pressure sores regularly.
2.8.19 NUTRITION
Mobilization out of bed is recommended soon after ICH according to patients’ 
tolerance to reduce risk of bronchoaspiration and effectively initiate rehabilitation. 
Tracheostomized patients are not protected from bronchoaspiration. Dysphagia has 
been reported to be present in as much as 50% of stroke patients, and causatively 
to associate with aspiration pneumonia.653 It is imperative that early nutrition is 
managed by nasogastric tube, and oral nutrition is cautiously and gradually resumed 
after evaluation and with the help of a speech therapist when the patient can swallow 
increasing volumes of water without coughing or changing of the voice.712-714 Until 
then, bedside water swallow test should be repeated daily. A proposition has been 
made that tube feeding should be halted for 4 hours during the night when the 
risk of gastric reflux is higher. If the need for nasogastric tube is prolonged due to 
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impaired consciousness parenteral nutrition admixture should be complemented. 
In case oral nutrition cannot be resumed within 2-4 weeks, percutaneous placement 
of an endogastric tube (PEG) may be beneficial.715 Weight loss of 5-10% in the first 
weeks after stroke is frequent.584,716
2.9 LONG-TERM OUTCOME OF INTRACEREBRAL  
 HEMORRHAGE
2.9.1 MORTALITY
As mentioned earlier, ICH is the most catastrophic subtype of strokes, with one-
month mortality of 40%, and great proportion of the survivors left with functional 
impairment.4,7,8,10,16,32,43,180,201,264-268,275,431,717,718263,268 Among the one-month survivors of 
ICH, risk for long-term mortality is highest in the first year following: 4.5-fold fold 
the risk in people from the general population.285 An average annual risk of death 
of 9.1% has been reported for long-term mortality among one-month survivors of 
stroke.267 In the subgroup analysis of this study, mortality was similar between those 
who had suffered ischemic stroke and those with ICH.267 According to another study, 
annual rate of vascular death in acute phase survivors of ICH is 3.2%.719 According 
to two recent meta-analyses, one-year mortality was 54%, including patients dying 
within the first 30 days.16,263 Five-year and 10-year mortality reached up to 71% and 
82%, respectively.263,268 Long-term mortality among stroke patients is mainly due 
to cardiovascular diseases, but also cancer, other diseases, accidents, and suicide 
are other significant causes of death in ICH patients.15,267 Higher age, male gender, 
diabetes, and heart failure have been reported to increase the risk of long-term 
mortality after ICH.15,267,285,719-721
Studies on ischemic stroke in young adults have revealed that young people with 
ischemic stroke have lower mortality, 7.9% at five years among one-month survivors, 
lower than their elder counterparts, but higher than general population.722-731 The 
very recent FUTURE study was the first to investigate long-term mortality after 
ICH at young age: among 91 one-month survivors 5-year, 10-year, and 20-year 
cumulative mortality were 6.1%, 10.3%, and 13.7%, respectively, with annual risk 
ranging between 0.6% to 2.9%.730 Half of the deaths of young victims of ischemic 
stroke are attributable to a vascular origin, but no similar data exist for young ICH 
patients.728,730,731
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2.9.2 STROKE RECURRENCE AND SECONDARY PREVENTION
Annual rate of ICH recurrence has been reported ranging from 1.3% to 7.4% by 
several studies.263,285,719,732-739 Investigators of one, relatively large, population-based 
study reported cumulative 5- and 10-year rates of recurrence of 9.6% and 14.2%, 
respectively.734 Age ≥65 years, lobar hematoma location, and previous ischemic 
stroke have been found to associate with increased risk for recurrence in multiple 
reports.263,719,733-736,738,739 Lobar location seems to be the most significant single 
risk factor with a 3.8-fold increased risk of recurrence.739 Hypertension has been 
reported associating with recurrence in some studies.732,738,740 IVH, OAC use, diuretic 
monotherapy, α- or β-blocker monotherapy, poor functional outcome after initial 
ICH, basal ganglion location of hematoma, and absence of hyperlipidemia, however, 
have been reported associating with recurrence in single studies.719,735-738 Diabetes is a 
risk factor known to increase risk for recurrent ischemic stroke, and a tendency with 
recurrent ICH was reported by one study.734,741 The only investigators to address ICH 
recurrence in the young very recently reported 10-year cumulative recurrence rate 
of 12.2%, all with the index ICH attributable to structural vascular malformations.254 
Approximately one third of the recurrent ICH occur within the first year following 
the initial ICH, but it may occur even up to 10 years.285,736,738,740 Mean and median 
interval between initial and recurrent ICH has been reported 30 (range from 2 to 
158) and 33 (range from 1 to 120) months.285,736 Among those with hypertensive ICH, 
initial and recurrent hemorrhages most often have different site of bleeding.270,740 
Between 24% and 70% of the recurrent ICH are fatal.285,736-738 Patients with ICH have 
even higher risk for ischemic stroke than ICH recurrence.733,739 Annual occurrence 
of vascular events in total, including all stroke subtypes and MI, is almost three-fold 
to ICH-recurrence, with higher age and male gender identified as predictors.719,742
Studies on stroke, particularly those of ischemic stroke in the young, have 
emphasized the need for aggressive stroke secondary prevention, likely as a life-
long endeavor.15,267,269,722-730,742 Hypertension is the single most important target 
for prevention of ICH recurrence.154,738,740 Specific data on the optimal BP are not 
available, but AHA recommends targeting <140/90, and <130/80 in the presence of 
diabetes or chronic kidney disease.154,743 Risk of recurrent ICH probably outweighs the 
risk of thromboembolism in patients with atrial fibrillation, and OAC use, therefore, 
should be avoided.152,154,285,719 Antiplatelet agents have substantially smaller effect 
on ICH recurrence and severity suggesting their use being safer than OAC.141,744 
As with primary prevention of ICH, appropriately frequent physical activity and 
avoiding smoking most likely are beneficial for secondary prevention also, though 
no published data exist. 
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2.9.3 REHABILITATION AND RECOVERY
Neuronal damage caused by ICH results in symptoms and subsequent disabilities 
depending on the location and magnitude of the brain injury. These disabilities 
may often present as one-sided motor paresis of upper, lower, or both extremities, 
paresthesia, dysarthria, dysphasia, and visual impairment. Other symptoms include 
neglect, vertigo, headache, central poststroke pain (CPSP), impaired memory, and 
other neuropsychological or cognitive handicaps.630,745 A recent study reported 
better survival and functional outcomes in patients for whom early rehabilitation 
was initiated within 48 hours following ICH.746 Initial evaluation by physical 
therapist, occupational therapist, speech therapist, and neuropsychologist is of grave 
importance, and intensive and well-organized multidisciplinary rehabilitation should 
begin in ICSU, since it has been shown to improve survival, recovery, and returning 
home.747,748 Early mobilization has been proposed to decrease complications, but 
avoiding falls, another complication of stroke, is also important.630,631,636,637,749 Once 
the patient is stable, no evidence of neurological deterioration is observed for several 
days, and patient’s condition improves, rehabilitation may be continued either as 
outpatient or in a rehabilitation center. Early supported discharge and home-based 
rehabilitation have shown to be cost-effective and to produce comparable results 
to conventional outpatient rehabilitation.748,750,751 Recovery is more rapid in the 
first weeks, but may continue for many months after ICH.293,718 Speed and grade 
of recovery are individual, and no hard rule exists on when recovery is over.154 
Cognition, mood, motivation, and social support all are important for recovery. 
Since the nature of poststroke disability is complex and includes physical and mental 
impediments, rehabilitation programs should be individually tailored and to enable 
lifestyle changes.154 Recovery after ICH can be improved through progress in the field 
of neurorehabilitation. Depending on stroke severity, a number of important long-
term consequences such as sick leave, prohibition for driving, and early retirement 
must be considered in working-age patients. Available consultation of social worker 
concerning the patients’ financial affairs is also in the best interest of the patient.
The disability caused by ICH is usually a complex combination of physical and 
mental impediments. Their nature is individual, and depends on the size, location, 
and severity of the brain tissue damage caused by hematoma. The pre-ICH condition 
and comorbidities likely affect also. Although data on functional outcome at long-
term after ICH has been reported by some studies, our knowledge regarding young 
patients remains limited. Glasgow Outcome Scale, mRS, and Barthel Index have 
commonly been used to measure the functional outcome. The independence rates 
have varied between 12% and 39%, but different end-points have been used in 
the studies.16 Approximately half of the survivors remain dependent on others on 
the daily living.276,281 Recovery differs between ischemic stroke and ICH, and ICH 
has been found to independently predict poor neurological outcome.752 Results, 
however, are partly contradictory, since two studies have reported ICH patients 
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making greater gains, while another study reported ICH patients to improve until 
10 weeks post-stroke, and ischemic stroke patients until 26 weeks.717,718,753 Another 
study, however, reported mRS score increasing in 34% of acute phase survivors of 
ICH between hospital discharge and 12 months, decreasing in 22%, and a proportion 
of patients improving even after 6 months.431 Same investigators found that besides 
early mortality, ICH score accurately predicts functional outcome at 12 months. This 
is in line with other reports.93,266,281,286 In addition, pre-ICH cognitive impairment also 
predicts poor functional outcome.281 As many of the strongly disabled patients die 
after the acute phase, the relative proportion of functionally independent patients 
increases over time.43 Spasticity may develop in those with motor hemiparesis – its 
prevalence in unselected ICH patients at 12 months is 36%.754
Young adults are usually living the most active and demanding phase of their 
lives, and often have many responsibilities. Many quality-weighted-years are, 
therefore, lost and the economic consequences for society are dire, when young 
adult becomes a victim of stroke.56 Treatment for stroke survivors, therefore, is 
of grave importance.755 This may include treatment for central post-stroke pain 
(CPSP), hemiplegic shoulder pain (HSP), painful spasticity, tension-type headache, 
fatigue, incontinence, sexual dysfunction, and sleep-disordered breathing.745,755-757 
The quality of life varies markedly among young victims of stroke. A deficit persists 
in 61%.758 Only one study has been composed to investigate young-onset ICH in 
particular.254 Among the 30-day survivors, poor functional outcome (mRS >2) was 
present in half of the survivors at 30 days. The proportion remained approximately 
the same in the long-term follow-up.759 Only 18% of the survivors, however, were 
dependent on daily life, when measured with Instrumental Activities of Daily Living 
(<8). In a Dutch cohort, after eight years from ICH, the young survivors still had 
2- to 3-fold risk for unemployment than the general population.760 
2.9.4 POST-STROKE DEPRESSION
Post-stroke depression (PSD), often measured by Beck Depression Index II (BDI-II), 
is a rather common neuropsychiatric complication of ischemic and hemorrhagic 
stroke. Mood depression is considered the strongest predictor of quality of life 
in stroke survivors.761-763 PSD occurring in approximately 30% of general stroke 
survivors has been reported by several studies and one meta-analysis.764-770 Among 
ICH patient cohorts, depressed mood (Hamilton Depression Rating Scale score 
>10) has been present in 20% of 596 patients in one study, and PSD detected by 
Zung Self-Rating Depression Scale in five out of twelve patients (42%).771,772 It has 
been reported occurring more often in the young stroke patients, females, and those 
with more severe symptoms, and hypertension.755,764-766,771,773-778 PSD also associates 
with increased cognitive impairment, disability, falls, and short- and long-term 
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mortality, as well as worse rehabilitation outcome.779-790 Conversely, absence of PSD 
predicts ability to return to work in the young, and recovery from PSD associates 
with functional improvement.790,791
PSD most likely is caused by combination of the brain injury and psychological 
reaction to the illness.792,793 Etiology of PSD has been proposed as a “complex 
mixture of prestroke personal and social factors, and stroke-induced social, 
emotional, and intellectual handicap”.794 One study reported symptoms of PSD 
being stable and chronic, while other studies have reported the prevalence of PSD 
being rather dynamic with some patients recovering and others becoming chronicly 
affected.766,769,794,795 A meta-analysis studied whether the lesion location associates 
with PSD, but no association was found.796 Multidisciplinary approach has been 
promoted to treat PSD.797
A major proportion of patients with PSD, unfortunately, go untreated.798 
Antidepressants have been reported to improve the outcome in patients even 
without clinical depression suggesting their possible beneficial effects on neural 
recovery.799-801 Even prophylactic use of antidepressants has been reported to 
improve the outcome, but the optimal timing and duration of the medication, and 
the best benefiting patients for the use of antidepressants is yet to be resolved.792,802,803 
In addition, multidisciplinary approach has been promoted to treat PSD.797 Reports 
on cognitive therapy have shown promising results.761,804-807 In addition to treating 
PSD, fluoxetine has also been reported to enhance motor recovery after ischemic 
stroke by modulating neural recovery, which may prove useful in the future.808
Anxiety, pain, and cognitive dysfunction also play a role in young ICH patients’ 
outcome.722 A recent retrospective study showed that 19% of young ischemic stroke 
patients had anxiety after 12 years follow up.809 Post-stroke fatigue occurs in 41% 
to 45% of stroke survivors, is predicted by anxiety and depression symptoms, and 
associates with poor functional outcome.810,811 Cognitive impairment is present 
among 50% of the survivors of ischemic stroke at young age, and subjective memory 
failures among as many as 86%.812,813 
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3 AIMS OF THE STUDY
I To define risk factors, etiology, clinical presentation, and neuroimaging 
characteristics in young patients with first-ever ICH and compare these features 
with older patients.
II To determine baseline clinical, treatment, and neuroimaging characteristics 
associated with increased early mortality in young patients with ICH.  
III  To describe acute medical complications and their impact on early mortality 
in young ICH patients.
IV To investigate long-term depression after young-onset ICH.
V To assess long-term mortality rates, functional outcome, and predictors of poor 
outcome for ICH in younger patients.
53
4 PATIENTS AND METHODS
At first, a retrospective single-center hospital-based cohort study of consecutive 
patients aged between 16 and 49 years with a first-ever non-traumatic ICH treated in 
the Helsinki University Hospital (HUH), Departments of Neurology, Neurosurgery, 
or both, between January 1, 2000 and March 31, 2010 was performed, the Helsinki 
ICH in the Young Study. Consent for registration was not required by the Finnish 
legislation as this was a registry-based study with no patient contact. Thereafter, we 
executed a prospective follow-up study of that cohort of patients. Written informed 
consent for participation was obtained from the surviving patients taking part in 
the follow-up study. Both studies have been approved by the Ethics Committee and 
institutional authorities of HUH.
Our hospital serves a population of 1.5 million inhabitants and has the only 
24/7 neurological and neurosurgical emergency units in the catchment area. All 
neurological emergency cases, particularly the young patients, are brought to 
emergency rooms at either of these units within our hospital’s catchment area – 
either directly or via other hospitals. As >95% of acute stroke cases in Finland are 
hospitalized, therefore, our series closely resembles a population-based study.44
4.1 PATIENT SELECTION
A total of 1325 patients aged 16 to 49, who at any time during their hospitalization 
or outpatient visit had an International Classification of Diseases, 10th Revision 
(ICD-10) diagnosis code of Q28.1, Q28.3, I60.8, I61, I67.3, I67.4, I67.5, I67.6, 
I67.7, I67.8, I67.9, I68 or I78, were screened by evaluation of patient records and 
imaging databases (Table 5). This set of ICD-10 codes was designed to cover all 
potential conditions where an ICH could emerge as e.g. AVM with ICH. Patients with 
imaging-verified first-ever episode of non-traumatic ICH were considered eligible. 
We excluded patients with ICH accompanied by SAH or subdural hemorrhage. 
Those with an aneurysm as the underlying cause of ICH were excluded, even if no 
clear SAH was present, since a small SAH always occurs in the rupture of cerebral 
aneurysm. Those treated initially outside of HUH and those with missing medical 
records were excluded. Patients with hemorrhagic transformation of a cerebral 
infarction with or without thrombolytic therapy were not screened and thus not 
included, since their primary disease was brain infarction. Those with a tumor or 
CVT as the cause of ICH were included. Those with a structural lesion without a 
bleeding episode were ineligible. Excluded patients appear in Table 6. Included 
patients in the Helsinki ICH in the Young Study amounted 336. For comparisons, 
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a cohort of ICH patients aged >50 years was used. This cohort includes patients 
treated due to non-traumatic first-ever ICH in HUH between January 2005, and 
March 2010, and data regarding this cohort was gathered similarly by retrospective 
analysis of medical chart notes, imaging, and laboratory databases.814
After an initial determination of mortality from our national cause-of-death 
registry, surviving patients received an invitation to participate in the follow-
up study, with those providing their written informed consent being included 
(Figure 11).
Table 5. ICD-10 codes used to identify patients from the hospital discharge registry.
ICD-10 code Explanation 
Q28.1 Precerebral aneurysm or arteriovenous malformation 
Q28.3 Cerebral aneurysm or arteriovenous malformation 
I60.8 Rupture of cerebral arteriovenous malformation 
I61 Intracerebral hemorrhage 
I67.3 Progressive vascular leukoencephalopathy 
I67.4 Hypertensive encephalopathy 
I67.5 Moyamoya disease 
I67.6 Nonpyogenic thrombosis of intracranial venous system 
I67.7 Cerebral arteritis, not elsewhere classified 
I67.8 Other specified cerebrovascular diseases 
I67.9 Cerebrovascular disease, unspecified 
I68 Cerebrovascular disorders in diseases classified elsewhere 
I78 Diseases of capillaries 
Table 6. Excluded patients
Reason for exclusion Number of patients
n=1325 (100)
No ICH 765 (57.7)
Primary subarachnoid hemorrhage 67 (5.1)
Trauma 57 (4.3)
Recurrent ICH episode 38 (2.9)
Missing patient records 20 (1.5)
Initially treated in another hospital 18 (1.4)
Aneurysm 11 (0.8)
Incorrect primary diagnosis of ICH 8 (0.6)
Subdural hemorrhage 5 (0.4)
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Figure 11. Inclusion scheme for the follow up study of ICH in the Young Study.
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Helsinki 
ICH in the Young Study 
336 (100.0%) 
Died within  
30 days after ICH onset 
55 (16.4%) 
Lost to follow-up 
13 (3.9%) 
30-day survivors 
281 (83.6%) 
Long-term mortality after 
ICH study population 
268 (79.8%) 
Died after 30 days  
from ICH onset 
32 (9.5%) 
Invitation to participate sent 
236 (70.2%) 
Declined participating in study 
on long-term functional 
outcome after ICH 
101 (30.1%) 
Initially consenting to  
participate
135 (40.2%) 
Functional outcome after  
ICH study population 
131 (39.0%) 
Withdrew consent 
4 (1.2%) 
Patients
examined and 
interviewed 
77 (22.9%) 
Patients only 
interviewed 
54 (16.1%) 
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4.2 CLINICAL DATA
4.2.1 RISK FACTORS AND STROKE SEVERITY
A chart review including patient medical records, imaging, and laboratory 
databases was performed. All patients had been seen by a neurologist or a 
neurosurgeon. The risk factors and symptoms at arrival and recorded GCS and 
NIHSS values were registered. If these were not reported in the medical records, 
they were reconstructed from diligent chart notes. Province-wide hospital notes of 
all specialties provided information on comorbidities and previous medications. 
Hypertension was considered a risk factor if (1) there was a mention of previously 
elevated blood pressure by patient, relatives, or medical records together with a 
left ventricular hypertension as a biomarker of hypertension; or (2) any pre-ICH 
use of blood pressure medication. Current smoking, heavy use of alcohol, type 1 
and type 2 diabetes mellitus, any liver disease, and a previous non-ICH-stroke 
as a risk factor were recorded if they were noted in the medical records. Cancer, 
atrial fibrillation, coronary artery disease, and heart failure diagnosed prior to 
ICH were considered as comorbidities.
4.2.2 ETIOLOGIC CLASSIFICATION
The etiologic classification was based on discharge notes, imaging data, pathological 
analysis from surgical preparates, and laboratory findings. Hypertension was 
considered the cause in case it was present in the absence of any other causes, 
and hematoma was located in basal ganglia, thalamus, deep periventricular white 
matter, brain stem, or cerebellum. Structural causes were identified by brain and 
vascular imaging, and most often verified by pathological analysis. CVT and vasculitis 
were diagnoses on the basis of MR imaging. Illicit drug use was established by a 
urine sample, and considered the cause if no other cause was evident. Liver disease, 
other coagulation deficits, hematologic disorder, and diabetic microangiopathy were 
considered the etiology in case no other cause was found, as well as anticoagulation 
or other medication. Eclampsia and syndrome of hemolysis, elevated liver enzymes 
and low platelet count (HELLP) were diagnosed per standard practice. If no cause 
was found, it was considered unknown. Underlying etiologies of ICH were classified 
according to “Structural-Medication-Amyloid angiopathy-Systemic or other disease-
Hypertension-Undetermined” classification scheme (SMASH-U) that was proposed 
fairly recently, with the exception, of including those with tumor in the category 
of structural causes, and those with CVT in the category of other causes.814 In this 
Thesis, we used a simplified modification of SMASH-U classification, and divided 
our patients in four categories: (1) hypertensive microangiopathy, (2) structural 
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causes, (3) other cause, and (4) unknown cause. In some substudies, we also used 
a two-class division in structural and non-structural (all the rest) causes.
4.2.3 TREATMENT DETAILS
Our patients were treated according to the institutional guidelines in the ICSU, 
regular stroke unit (ward), general or neurosurgical ICU, or at the neurosurgical 
ward. All the ICUs can treat patients requiring ventilator support. We recorded 
neurosurgical operations performed. As this was a retrospective study, our 
criteria for operative treatment did not follow any predetermined scheme and 
was not systematically guided by any guideline. Operative treatment was thus 
performed using individual consideration in patients with a large ICH, declining 
GCS, symptomatic hydrocephalus, or imminent brain herniation who were still 
considered salvageable. The evacuation of the hemorrhage was always performed 
through a small open craniotomy using standard microsurgical techniques and a 
neurosurgical high magnification microscope. Mini-invasive or other experimental 
surgical techniques were not used. If needed, image-guided neuronavigation was 
used to localize the lesion. In patients with a ruptured AVM, the primary surgical 
goal was to occlude and remove the malformation. Obstructive hydrocephalus was 
treated with an EVD inserted through a standard frontal paramedian burr hole. In 
case IVH was present, intraventricular injection of tissue plasminogen activator was 
used. Finally, as a last resort, a decompressive hemicraniectomy was performed on 
patients with an uncontrollable high intracranial pressure.
Use of nasogastric tube, intubation, tracheostomy, central venous catheter, 
urinary tract catheter, antibiotic treatment, compression stockings, and low-
molecular-weight-heparin was recorded. Vomiting as a risk factor for aspiration 
and potential cause of electrolyte disorders, or hypoglycemia was recorded. Our 
written institutional stroke treatment guidelines have recommended treatment of 
hyperglycemia with subcutaneous insulin every hour until level of plasma glucose 
<8.0 mmol/L is reached. Intravenous insulin is used in treatment-resistant cases. 
Intravenous fluids with calculated percentage of sodium and potassium are 
administered to patients routinely to correct sodium or potassium disturbances if 
present. Early rehabilitation included physiotherapy, speech therapy, occupational 
therapy, and neuropsychological rehabilitation when judged necessary by the 
clinician. Length of hospital stay was recorded.
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4.2.4 MEDICAL COMPLICATIONS
Medical complications suffered by the patients any time during their acute hospital 
stay due to ICH were recorded, including infections, venous thrombotic events, 
cardiac complications, renal failure, hypoglycemia, hyperglycemia, sodium or 
potassium imbalances, bedsores, and gastric ulcers.
Pneumonias verified as infiltrate in chest radiograph together with fever, 
aural temperature >38 °C, and tracheal infections verified by bacterial growth in 
tracheal culture in intubated or tracheostomized patients, were both considered 
as respiratory infections.650 Septicemia was defined by bacterial growth in blood 
culture together with fever. Urinary tract infections (UTI) were registered by positive 
urine dipstick for nitrate or pyuria together with bacterial growth in urine sample 
culture. Meningitis was recorded by bacterial growth in cerebrospinal fluid sample 
accompanied by fever. Gastrointestinal infection was diagnosed by diarrhea or 
peritonitis verified in laparotomy.
DVT was recorded only when verified by ultrasound imaging of veins, and 
pulmonary embolism (PE) had to be verified by pulmonary CT angiography imaging. 
Cardiac complications comprised of first-ever atrial fibrillation, atrial flutter, and 
ventricular fibrillation diagnosed by ECG or myocardial infarction verified by ECG 
and elevated myocardial enzyme levels.
4.3 NEURORADIOLOGICAL DATA
Brain imaging was performed on admission to the hospital within 24 hours of 
the first observation of the symptoms. Initial head CT, MRI, and any angiography 
performed to define the underlying cause were investigated. All the scans were 
initially evaluated by neuroradiologists. Measurements and classification of ICH 
were performed on digital images. ICH originating at the cortex and subcortical 
junction were classified as lobar, whereas ICH exclusively involving the thalamus, 
basal ganglia, internal capsule, and deep periventricular white matter were classified 
as deep ICH. Infratentorial ICH of cerebellum or brainstem, and solitary IVH were 
initially classified separately. Solitary IVH was, however, analyzed as a deep ICH. 
Intracerebral hemorrhages involving more than one parenchymal site were classified 
as mixed, as reported previously.283,815 Location of ICH in uncertain cases was decided 
by mutual consensus. Volumes were calculated with the ABC/2 method.288 IVH was 
recorded, but not included in volume calculations. ICH was classified as multiple 
if more than one separate sites of bleeding without connecting hematoma-bridge 
between the clots. Hydrocephalus was defined as increased radius or decreased 
ventricular angle in frontal horns, rounding and enlargement of atrium with sulcal 
effacement, increased width of third ventricle, or ballooning of fourth ventricle.279 
Cingulate herniation was defined as at least 8 mm of horizontal displacement of 
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pineal body from the midline.292 Any displacement of brain parenchyma behind 
tentorium or through the foramen magnum was also classified as herniation.
4.4 LABORATORY DATA
Hyperglycemia was defined as plasma glucose >8.0 mmol/L (>144mg/dL) at any 
time during acute hospital ward. Hypoglycemia was defined as plasma glucose <4.0 
mmol/L (72mg/dL).568 Renal failure was defined as plasma creatine level >100 
μmol/L measured by enzymatic method. Highest and lowest plasma sodium and 
potassium levels during hospital stay were recorded, and were defined as normal by 
the range of values used by the laboratory of Helsinki University Hospital: 136-145 
mmol/L (313-333 mg/dL) for sodium and 3.3-5.0 mmol/L (12.9-19.6 mg/dL) for 
potassium. Use of bacterial culture sample from cerebrospinal fluid, urinary tract 
catheter, and tracheostomy or intubation tube was recorded.
4.5 MORTALITY AND INCIDENCE DATA
The primary outcome measure was 3-month all-cause case-fatality. Secondary 
outcome measures were mRS score at discharge, reconstructed according to 
discharge notes, and in-hospital mortality. Discharge to rehabilitation center or 
home was also recorded. Mortality and demographic data, to calculate incidence of 
ICH, were obtained from Statistics Finland initially on June 25, 2013. For the long-
term follow-up studies, we performed a second data collection on June 16, 2014.
4.6 POST-STROKE DEPRESSION
PSD at follow-up was assessed with structured questionnaires. Due to the severe 
aphasia and substantially impaired cognition, one patient taking part in the follow 
up study was excluded from the analyses of PSD. Beck Depression Inventory II (BDI-
II) was used to identify patients with depression, Hospital Anxiety and Depression 
Scale (HADS) was used to identify patients with anxiety, Pain Anxiety Symptoms 
Scale (PASS-20) to verify pain-related anxiety, and Brief Pain Inventory (BPI) to 
identify patients with pain. Several different questionnaires have been used to detect 
PSD, BDI-II being one of them.771,777,792,816,817 BDI-II and HADS have been accepted 
as relevant tools to measure prevalence of PSD.818 Montreal Cognitive Assessment 
(MoCA) was performed on all those patients invited to a clinical follow-up, except 
one who was unable to comprehend the tasks. In stroke patients, MoCA has been 
validated as a screening measure of cognitive impairment.819-822 Fatigue was assessed 
by three fatigue-related questions in BDI-II.
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4.7 FUNCTIONAL OUTCOME
After mortality check on June 25, 2013 surviving patients living within a 50 km 
radius of HUH were invited to a clinical follow-up, amounting 77. Those participating 
underwent detailed neurological examination by a single investigator. Those living 
more distant than 50 km were interviewed with a structured questionnaire by mail 
and telephone, and they numbered 54. Employment status, Barthel Index score 
(BI), residual symptoms, presence of post-ICH epilepsy, and recurrent strokes 
reported by the patients were verified by medical records. Degree of disability was 
measured by the mRS score, judged as well by a single investigator on the basis of 
clinical follow-up or interview.823 The definition of unfavorable functional outcome 
at follow-up was mRS 2 to 5. Employment and marital status were recorded, as 
well as dwelling. Patient’s quality of health was measured by EuroQualityOfHealth-
5D-3L –questionnaire (EQ-5D).824 Since no health value sets have been recorded 
for the Finnish population, Danish value sets were used instead. Those patients 
with no information of mortality, and no real-time contact information in hospital 
database were lost to follow-up. Those patients, numbering 13, were from foreign 
countries and visiting Finland at the time of their ICH.
4.8 STATISTICAL METHODS
Continuous variables were tested for normal distribution and reported as medians 
with interquartile range (IQR). Categorical variables were compared with Chi-square 
and Fisher’s exact test. Mann-Whitney-U test, and Kruskal-Wallis test were used 
to compare continuous variables with skewed distribution of 2 or >2, respectively. 
A two-sided P value <0.05 was considered significant. All analyses used SPSS 22 
for Windows (IBM Inc., Armonk, NY, USA).
4.8.1 BASELINE DATA
Incidence of ICH was calculated according to demographic data on residents in the 
area of Helsinki and Uusimaa Hospital District between January, 2000 and March 
2010. Age was categorized into 3 groups for analysis of trends: 16 to 29 years, 30 to 
39, and 40 to 49 years. Additionally, all these 336 patients aged between 16 and 49 
were compared to patients aged between 50 and 99 registered in the Helsinki ICH 
Study, numbering 921. Comparisons concerning age, gender, risk factors, etiology, 
NIHSS score, imaging, treatment and hematoma volume were performed.
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4.8.2 PREDICTORS OF EARLY MORTALITY
Predictors of 3-month mortality were analyzed on patients aged between 16 and 49 
years as well as those over 49. Multivariate analysis with binary logistic regression 
using backwards likelihood ratio method was performed separately in patients 
aged 16 to 49 years (n=319), 50 to 59 years (n=182), 60 to 69 years (n=261), 70 
to 79 years (n=267), and 80 to 99 years (n=195) to identify factors independently 
associated with 3-month case-fatality in the age-specific subgroups. Six patients 
with tumor as the etiology of ICH, and eleven patients with missing imaging data 
were excluded in this multivariate analysis. Covariates for logistic regression were 
selected based on previous studies on ICH mortality and variables with P-value 
<0.5 in univariate analysis. NIHSS score instead of GCS was used in our analyses, 
since NIHSS involves more information on the patient’s condition, including the 
level of consciousness (items 1a, 1b, and 1c).
A separate univariate analysis and multivariate analysis with binary logistic 
regression using backwards likelihood ratio method, and confounding factors 
included, was performed to define whether initial hydrocephalus, multiple 
hemorrhages, herniation, or any neurosurgical procedure, including hematoma 
evacuation, decompressive craniectomy, and insertion of EVD, associate with 
increased 3-month mortality. In this analysis baseline ICH volume was categorized 
as 0-29 ml, 30-60 ml, and >60 ml. NIHSS scores were analyzed in three categories: 
0-6, 7-14, and >14, reflecting mild, moderate, and severe symptoms. To further 
assess the impact of early surgery on mortality, a propensity score for the probability 
of hematoma evacuation was calculated based on variables influencing treatment 
decisions (age, sex, NIHSS score, hematoma location and volume, structural cause, 
presence of IVH, hydrocephalus, herniation, and multiple hemorrhages), and 
patients undergoing surgery were matched to those not undergoing surgery using 
the nearest-neighbor-matching method. Patients operated were then compared 
with those not operated.
To study the impact of medical complications on mortality, we constructed 
a binary logistic regression model using complications associated with 3-month 
mortality in univariate analysis with adjustment for confounding factors as 
covariates. These covariates included age, gender, hematoma volume, infratentorial 
hematoma location, presence of intraventricular hemorrhage, NIHSS score, and 
hematoma evacuation. Urinary tract infection was excluded from this analysis due 
to possible observational bias. Because preexisting diabetes and hyperglycemia are 
intercorrelated, we forced diabetes in the model. To illustrate the additive impact of 
multiple different complications, we also performed a multivariable analysis with 
number of complications (score) as a covariate instead of individual complications.
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4.8.3 POST-STROKE DEPRESSION
Presence of PSD was classified as having more than 13 points measured by BDI-
II.816,818,825 HADS was used to find the proportion of patients with symptoms of 
depression (more than 11 points measured by HADS-total), and with symptoms of 
anxiety (more than 6 points measured by HADS-total).825,826 Pain-related anxiety was 
defined as having more than 30 points by PASS-20.827 Pain was defined non-existent, 
mild, moderate, or severe by BPI scores 0, 1-48, 49-72, and 73-120, respectively.828 
Mild cognitive impairment was defined by the MoCA score between 18 and 26; 
moderate cognitive impairment between 10 and 17; and severe cognitive impairment 
less than 10. Results were analyzed between males and females and between 3 
patient age groups (from 16 to 29, from 30 to 39, and from 40 to 49 years at 
ICH onset). The effect of ICH treatment was analyzed by comparing those who 
had hematoma surgically evacuated with those who had no hematoma evacuation. 
Correlations between the degree of disability were measured by the mRS. Univariate 
analysis was performed to identify factors associated with PSD including gender, 
age, hypertension, diabetes, cardiac diseases, hematoma volume IVH, infratentorial 
hematoma location, arrival NIHSS score, presence of herniation, hydrocephalus, 
or multiple hemorrhages, hematoma evacuation, follow-up mRS, MoCA, BPI, and 
PASS-20 score, as well as current employment and living alone. Logistic regression 
analysis with backwards likelihood ratio method was performed with factors with 
tendency to associate with PSD (P<0.1) in our univariate analysis.
4.8.4 LONG-TERM OUTCOME
To define patients’ residual symptoms and current mRS, 77 (22.9%) patients 
underwent clinical examination and interview, whereas 54 (16.1%) were interviewed 
only by telephone and structured questionnaire. Baseline data was compared 
between those patients included in the follow-up study and those excluded due to 
being lost, refusing to participate, and withdrawing their consent. Life table function 
served to calculate cumulative survival rates, cumulative ICH recurrence rates, and 
cumulative rates for late seizures after ICH. Univariate Cox regression analysis served 
to create hazard ratios and their 95% CIs. Known factors associated with mortality 
in the studies of ICH were included in the univariate analysis, including gender, age, 
hypertension, diabetes, cardiac diseases, arrival NIHSS score, hematoma volume, 
infratentorial hematoma location, presence of IVH, hydrocephalus, herniation, 
or multiple hematomas, and structural etiology, as well as surgical hematoma 
evacuation. In addition to age and sex, factors tending to associate with mortality 
(P<0.1) were entered in a multivariable Cox regression model to identify independent 
factors associated with mortality. Kaplan-Meier survival analysis using the log-rank 
test was also performed to compare long-term mortality between surgically and 
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non-surgically treated patients. For analysis of unfavorable outcome (mRS 2-5) at 
follow-up, we first tested the same baseline factors as in the survival analysis in 
a univariate analysis. Subsequently, we constructed a binary multivariate logistic 
regression model with a backward likelihood-ratio method to identify factors 
independently associated with unfavorable outcome. This analysis included age, 
gender, and parameters tending to associate with unfavorable outcome (P<0.1). 
Data from EQ-5D were analyzed with linear regression using backward method 
with demographic factors and those with association in univariate analysis.
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5 RESULTS
5.1  CLINICAL AND RADIOLOGICAL FEATURES OF  
 THE STUDY POPULATION
A total of 336 patients (200 [59.5%] males, between the age of 16 and 49 years 
(median age 42 [IQR 34-47]; males 42 [34-46], females 44 [33-47]; P=0.471) were 
eligible (Figure 12).
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5 RESULTS
5.1 Clinical and radiological features of the study population
A total of 336 patients (200 [59.5%] males, between the age of 16 and 49 years (median age 42 [IQR 
34-47]; males 4  [34-46], females 44 [33-47]; P=0.471) were eligible (Figure 12). 
Figure 12. Age- and gender distribution of patients included 
5.1.1 Incidence 
The annual incidence of ICH was 4.9 (95% CI 4.5-5.3) cases per 100 000 population, being 6.2 (5.0-
7.3) in males and 4.0 (3.4-4.7) in females. The incidence increased with age, being 2.6 (2.1-3.1) for 
age group 18 to 29 years, 3.0 (1.1-4.9) for 30 to 39 years, and 9.2 (7.5-10.9) for those aged 40 to 49 
years. The annual incidence ranged from 3.0 to 6.0 per 100 000 with no clear trend over time 
(P=0.206).
5.1.2 Risk factors and etiology of ICH 
The most common risk factor was hypertension (29.8%), particularly in males (34.5%), while almost 
absent in those between age 16 and 29 (3.2%). Heavy drinking was more prevalent in males (20.0%). 
Those with no risk factors amounted 126 (37.5%). Comparing the young patients to 921 patients over 
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Figure 12. Age- and gender distribution of patients included
5.1.1 INCIDENCE
The annual incidence of ICH was 4.9 (95% CI 4.5-5.3) cases per 100 000 population, 
being 6.2 (5.0-7.3) in males and 4.0 (3.4-4.7) in females. The incidence increased 
with age, being 2.6 (2.1-3.1) for age group 18 to 29 years, 3.0 (1.1-4.9) for 30 to 39 
years, and 9.2 (7.5-10.9) for those aged 40 to 49 years. The annual incidence ranged 
from 3.0 to 6.0 per 100 000 with no clear trend over time (P=0.206).
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5.1.2 RISK FACTORS AND ETIOLOGY OF ICH
The most common risk factor was hypertension (29.8%), particularly in males 
(34.5%), while almost absent in those between age 16 and 29 (3.2%). Heavy drinking 
was more prevalent in males (20.0%). Those with no risk factors amounted 126 
(37.5%). Comparing the young patients to 921 patients over 49 years of age with ICH 
(median age 70 years [61-79]), the young had significantly less often hypertension 
(P<0.001), type 2 diabetes mellitus (P<0.001), and cardiac disease (coronary heart 
disease, heart failure, or atrial fibrillation, P<0.001). The most prevailing etiology 
was hypertensive microangiopathy (25.0%). Structural lesions, mostly AVMs or 
cavernous hemangiomas, altogether caused approximately one-fourth of all ICH 
(26.5%). Systemic diseases and other conditions accounted for 16.4% of ICH. In one-
third of our patients the etiology was undetermined (Table 7). The four-dimensional 
distribution of etiologies appears in Figure 13. Hypertensive microangiopathy 
(P=0.002), CAA (P<0.001), and medication (P<0.001) were considerably more 
frequent causes of ICH among the elderly while a structural (P<0.001), systemic, 
and other (P<0.001) or unknown cause (P<0.001) was substantially more prevalent 
among the young. 
5.1.3 SYMPTOMATOLOGY
Symptoms upon arrival included motor hemiparesis (57.1%), headache (48.8%), 
nausea (35.7%), sensory hemiparesis (27.7%), vomiting (26.8%), dysphasia/aphasia 
(31.3%), dysarthria (24.4%), seizure (11.6%), disorientation (11.3%), vertigo (9.2%), 
Figure 13. Distribution of underlying etiologies of ICH
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Factor  
Number of patients 336 
Males 200 (59.5) 
Age 42 [34-47] 
Risk factors  
          Hypertension 100 (29.8) 
          Smoking 75 (22.3) 
          Excessive alcohol use 49 (14.6) 
          Diabetes, type 1 17 (5.1) 
          Previous stroke 14 (4.2) 
          Liver disease 12 (3.6) 
          Diabetes, type 2 12 (3.6) 
          Cardiac disease * 11 (3.3) 
          Cancer 6 (1.8) 
Hematoma characteristics  
          Hematoma volume (mL) 11 [3-36] 
          Intraventricular hemorrhage 117 (34.8) 
          Infratentorial loc tion 52 (15.5) 
NIH Stroke Scale score 8 [2-19] 
GCS score 15 [10-15] 
Etiology structural  
          AVM 45 (13.4) 
          Cavernoma 36 (10.7) 
          Brain tumor 6 (1.8) 
          Epitheloid hemangioendothelioma 1 (0.3) 
          Capillary teleangiectasy 1 (0.3) 
Etiology non-structural  
          Hypertensive microangiopathy 84 (25.0) 
          Systemic disease 55 (16.4) 
          Unknown 108 (32.1) 
Data are n (%) or median [interquartile range].  
Table 7. Baseline characteristics of young ICH patients treated in the Helsinki University 
Hospital between January, 2000 and March, 2010. 
0%
5%
10%
15%
20%
25%
30%
35%
Hypertensive
microangiopathy
Structural Other Unknown
66
5 RESULTS
visual field deficit (6.8%), ataxia (6.0%), and diplopia (5.4%). One out of five patients 
had severely decreased level of consciousness (GCS < 9, 21.4%). Males had 45% 
larger median baseline hematoma volumes than females (P=0.024). ICHs caused 
by hypertensive microangiopathy were 119% larger than hemorrhages caused by 
a structural cause, but 29% smaller than ICH caused by other diseases, and 54% 
smaller than ICH caused by unknown etiology (P<0.001) (Figure 14). The NIHSS 
scores at arrival were lower among the young (8 [2-19] vs. 12 [5-20], P<0.001), 
but no difference was detected in the hematoma volumes (11 [3-36] vs. 11 [4-30] 
mL, P=0.823). IVH was more often present (52.4% vs. 19.0%, P=0.001), and 
hematomas were larger (20 [9.2-34] ml vs. 5.9 [0.7-23] ml, P=0.014) among those 
with hydrocephalus in comparison to those without.
Table 7. Baseline characteristics of young ICH patients treated in  
the Helsinki University Hospital between January, 2000 and March, 2010.
Factor
Number of patients 336
Males 200 (59.5)
Age 42 [34-47]
Risk factors
          Hypertension 100 (29.8)
          Smoking 75 (22.3)
          Excessive alcohol use 49 (14.6)
          Diabetes, type 1 17 (5.1)
          Previous stroke 14 (4.2)
          Liver disease 12 (3.6)
          Diabetes, type 2 12 (3.6)
          Cardiac disease * 11 (3.3)
          Cancer 6 (1.8)
Hematoma characteristics
          Hematoma volume (mL) 11 [3-36]
          Intraventricular hemorrhage 117 (34.8)
          Infratentorial location 52 (15.5)
NIH Stroke Scale score 8 [2-19]
GCS score 15 [10-15]
Etiology structural
          AVM 45 (13.4)
          Cavernoma 36 (10.7)
          Brain tumor 6 (1.8)
          Epitheloid hemangioendothelioma 1 (0.3)
          Capillary teleangiectasy 1 (0.3)
Etiology non-structural
          Hypertensive microangiopathy 84 (25.0)
          Systemic disease 55 (16.4)
          Unknown 108 (32.1)
Data are n (%) or median [interquartile range]. 
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Table 8. Patient characteristics and operative treatment
Factor All
(n=325)
Evacuation 
of hematoma
(n=102)
P-value Decompressive 
craniectomy
(n=6)
P-value Ventricu-
lostomy
(n=31)
P-value
Sex 0.917 0.637 0.820
      Males 193 (59.4) 61 (59.8) 3 (50.0) 19 (61.3)
      Females 132 (40.6) 41 (40.2) 3 (50.0) 12 (38.7)
Age (years) 0.137 0.059 0.031
      16-29 57 (17.5) 23 (22.5) 2 (33.3) 7 (22.6)
      30-39 65 (20.0) 23 (22.5) 3 (50.0) 11 (35.5)
      40-49 203 (62.5) 56 (54.9) 1 (16.7) 13 (41.9)
NIHSS Score 0.047 0.044 <0.001
      0-6 146 (44.9) 39 (38.2) 1 (16.7) 7 (22.6)
      7-14 64 (19.7) 17 (16.7) 0 1 (3.2)
      >14 115 (35.4) 46 (45.1) 5 (83.3) 23 (74.2)
Location of ICH <0.001 0.583 0.019
    Lobar hemisphere 68 (20.9) 19 (18.6) 0 0
    Deep hemisphere 142 (43.7) 29 (28.4) 3 (50.0) 16 (51.6)
    Infratentorial 52 (16.0) 18 (17.6) 1 (16.7) 8 (25.8)
    Mixed 63 (19.4) 36 (35.3) 2 (33.3) 7 (22.6)
Volume of ICH <0.001 0.438 0.492
    0-29ml 231 (71.1) 48 (47.1) 3 (50.0) 21 (67.7)
    30-60ml 51 (15.7) 23 (22.5) 2 (33.3) 7 (22.6)
    >60ml 43 (13.2) 31 (30.4) 1 (16.7) 3 (9.7)
IVH present 117 (36.0) 42 (41.2) 0.189 3 (50.0) 0.471 23 (74.2) <0.001
Hydrocephalus 86 (26.5) 33 (32.4) 0.103 5 (83.3) 0.001 22 (71.0) <0.001
Multiple 
hemorrhages
25 (7.7) 3 (2.9) 0.030 0 0.475 1 (3.2) 0.326
Herniation 48 (14.8) 28 (27.5) <0.001 2 (33.3) 0.196 6 (19.4) 0.449
Etiology structural 84 (25.8) <0.001 4 (66.7) 0.021 11 (35.5) 0.197
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Figure 14: Median baseline ICH volumes according to clinical and radiological subgroup. 
NIHSS, National Institutes of Health Stroke Scale; HM, hypertensive microangiopathy; IVH, intraventricular hemorrhage; * p<0.05
Figure 14. Median baseline ICH volumes according to clinical and radiological subgroup.
NIHSS, National Institutes of Health Stroke Scale; HM, hypertensive microangiopathy; IVH, 
intraventricular hemorrhage; * P<0.05
5.1.4 IMAGING
A brain CT scan was performed in 328 (97.6%), brain MRI in 142 (42.3%), brain CT 
angiography in 147 (43.8%), brain MR angiography in 51 (15.2%), and DSA in 55 
(16.4%) of the patients. Any angiography was performed in 204 (60.7%) of all the 
patients. Structural etiologies were defined as the etiology of ICH more frequently 
in those who underwent either MRI (P<0.001), or any angiography (P=0.035), 
or both (P=0.002). The cause was considered hypertensive microangiopathy less 
frequently if MRI (P=0.007), or angiography (P<0.001) was performed, and the 
cause remained less often unknown in those who underwent MRI (P=0.006). Other 
causes combined, excluding medication, were more frequently seen in those on 
whom both MRI and angiography (P=0.023) were performed. Young patients 
received more often comprehensive imaging and intensive treatment including 
intubation and neurosurgical procedure in comparison to the elderly.
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5.1.5 TREATMENT
During their hospital stay, 32.1% of patients received treatment in ICSU, 53.6% 
received treatment in a neurosurgical unit, and 33.9% had a neurosurgical 
procedure, including hematoma evacuation among 31.3% (49% within a day of 
ICH), placement of EVD among 9.8% (47% within a day and 73% within 3 days of 
ICH), and decompressive craniectomy among 1.8% (median 3 [2-5] days) (Table 8). 
Those patients who received treatment in a general or neurosurgical ICU amounted 
to 53.0%.
Hematoma volumes were significantly larger in surgically versus non-surgically 
treated patients (36.1 mL [13.7-65.4] vs. 7.6 mL [1.7-21.9], p<0.001). Notably, 
operated patients with herniation had significantly larger hematomas than those 
not operated (80.2 [44.2-114.6] ml vs. 40.2 [17.3-50.1] ml, P=0.033), while the 
distribution of hematoma location did not markedly differ. Subfalcine herniation 
was recorded in 40 (12.3%) patients, transtentorial herniation in 16 (4.9%) patients, 
and downward cerebellar herniation in 4 (1.2%) patients. Median highest and lowest 
levels of plasma glucose, sodium, potassium, and creatinine are presented in Table 9.
5.2 MEDICAL COMPLICATIONS
Hyperglycemia was the most frequent complication (50.8%), followed by 
hyponatremia (44.9%), hypopotassemia (32.0%), and hypernatremia (28.0%). 
Respiratory infection was the most common of infections. Electrolyte disturbances, 
respiratory infection, meningitis, renal failure and arrhythmias were associated with 
initial stroke severity (Table 10).
Table 9. Highest and lowest levels of plasma glucose, sodium, potassium, and creatinine 
during acute phase in young adults with intracerebral hemorrhage.
Factor Highest Lowest Range
Glucose (mmol/L) 8.1 (6.5-10.1) 5.5 (4.9-6.2) 2.7-30.5
Sodium (mmol/L) 143 (141-147) 137 (134-139) 115-166
Potassium (mmol/L) 4.3 (4.0-4.6) 3.5 (3.2-3.7) 2.0-7.8
Creatinine (μmol/L) 75 (62-92) 59 (47-74) 18-831
Data are median (IQR) highest and lowest recorded values and range during acute phase.
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Table 10. Association of in-hospital complications and stroke severity in young adults with 
intracerebral hemorrhage.
Complication NIHSS score at arrival P-value
All (n=325) 8 (2-19) N.A.
Infections (n=110) 18 (10-28) <0.001
    Sepsis (n=7) 13 (5-20) 0.602
    Respiratory infection (n=82) 18 (10-28) <0.001
    Meningitis (n=2) 33 (31-34) 0.040
    Gastric infection (n=4) 10 (7-12) 0.838
    Urinary tract infection (n=40) 14 (7-19) 0.054
Deep venous thrombosis (n=11) 10 (3-15) 0.755
Pulmonary embolism (n=4) 12 (8-15) 0.715
Arrhythmia (n=4) 27 (20-34) 0.016
Renal failure (n=59) 15 (4-21) 0.007
Hyperglycemia (n=165) 12 (4-28) <0.001
Hypoglycemia (n=15) 18 (10-26) 0.020
Hyponatremia (n=146) 11 (2-21) 0.006
Hypernatremia (n=91) 18 (8-28) <0.001
Hypopotassemia (n=104) 16 (7-26) <0.001
Hyperpotassemia (n=27) 21 (8-32) 0.002
NIHSS, National Institutes of Health Stroke Scale
Data are median (IQR).
Respiratory infections (P<0.001), meningitis (P=0.049), hyperglycemia (P<0.001), 
hyponatremia (P<0.001), hypernatremia (P<0.001), and hypopotassemia (P=0.022) 
were more common among those who received surgical treatment. Furthermore, 
use of endotracheal intubation (P<0.001), tracheostomy (P<0.001), nasogastric 
tube (P<0.001), central vein catheter (P<0.001), and administration of antibiotics 
(P<0.001) were more frequent in patients undergoing surgical treatment.
Respiratory infection was not associated with vomiting as a symptom of ICH 
(27.4% vs. 24.5%, p=0.598). However, it was significantly more common among 
those intubated or tracheostomized than those who did not need ventilatory support 
(44.1% vs. 4.5%, p<0.001, and 84.9% vs. 17.4%, p<0.001, respectively). Vomiting was 
not associated with hypoglycemia or sodium or potassium disturbance. However, it 
was more often present in those who suffered from hyperglycemia (33.3% vs. 18.1%, 
p=0.002). DVT and PE were infrequent, yet medical prophylaxis with subcutaneous 
enoxaparin or dalteparin had been used in 9 of 11 (82%), and compression stockings 
in 5 of 11 (45%) of patients with DVT. 
None of our young patients suffered from ischemic heart event, bed sores or 
gastric bleeding. Arrhythmias recorded included one brief ventricular fibrillation in 
a patient who was successfully resuscitated. One flutter and two new-onset atrial 
fibrillations were also diagnosed during the hospital stay. Out of 59 patients with 
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5 RESULTS
renal failure, pre-ICH creatinine level was available in 27 (45.8%) patients, 18 of 
which had already then renal failure, and post-ICH chronic phase creatinine level 
was available in 37 patients, 17 (45.9%) of which had persisting renal failure.
Respiratory infection (P<0.001), urinary tract infection (P=0.005), hypoglycemia 
(P=0.033), hyperglycemia (P<0.001), hyponatremia (P<0.001), hypernatremia 
(P<0.001), hypopotassemia (P<0.001) and hyperpotassemia (P=0.016) reduced the 
proportion of patients discharged to home, while respiratory infection, meningitis, 
urinary tract infection, DVT, hyponatremia, hypernatremia and hyperpotassemia 
increased the length of median hospital stay (Table 11).
5.3 PREDICTORS OF EARLY MORTALITY
In-hospital mortality was 14.9% (n=50) with median length of stay being 13 days 
(IQR 5-18). Mortality at 3 months was 17.0% (n=57), half of these occurring within 
3 days and 95% within 19 days of ICH. A do-not-resuscitate decision was made in 
46 patients (13.7%) and a total of 22 patients were declared brain dead and organ 
donor candidates. At discharge, one third (37.5%) of the patients were functionally 
independent (mRS from 0 to 2).
5.3.1 COMPARISON BETWEEN THE YOUNG AND OLDER PATIENTS
Three-month mortality was substantially lower among the young than the elderly 
(17.0% vs. 32.7%, P<0.001). More thorough imaging performed in opposite to CT 
only, and treatment in ICSU in comparison to ICU decreased mortality, while DNR 
order and intubation increased mortality in the young and the elderly.
In patients aged 16-49, 50-59, 60-69, 70-79, and 80-99 hematoma volume had 
no trend with age (P=0.324). In all age groups, hematoma volume, NIHSS score 
at arrival, and IVH correlated with mortality at 3 months in univariate analysis. In 
logistic regression analysis of 3-month mortality performed separately for age groups 
including gender, NIHSS score, hematoma volume, IVH presence, infratentorial 
hematoma location, hypertension, cardiac disease, diabetes, and ICH etiology, the 
only factor significant in each age group was arrival NIHSS score, while hematoma 
volume was associated with mortality in all older age groups but not in the young 
patients.
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5.3.2 EFFECT OF SURGICAL HEMATOMA EVACUATION
In addition to severe symptoms (P<0.001), non-structural ICH etiology (P=0.006), 
infratentorial or mixed hematoma location (P<0.001), hematoma volume of 
>30 ml (P=0.031), multiple hematomas (<0.001), presence of IVH (P<0.001), 
hydrocephalus (P<0.001), and brain herniation (P<0.001) associated with higher 
3-month mortality of young adults after suffering ICH in univariate analysis. On the 
contrary, hematoma evacuation was associated with a lower risk of death (P=0.003). 
Of the 48 patients with imminent herniation, 28 (58.3%) underwent surgical 
hematoma evacuation, and mortality among those operated was significantly lower 
than among those not operated (17.9% vs. 85.0% p<0.001). No correlation emerged 
between mortality and EVD or decompressive craniectomy.
In multivariate analysis, independent factors associated with increased 
3-month mortality were more severe symptoms, infratentorial hematoma location, 
hydrocephalus, multiple hemorrhages, and herniation. However, age 30-39, age 
40-49, and hematoma evacuation were significant factors associated with lower 
mortality. Even if age was removed from the model, the effect of surgical evacuation 
remained the same (OR 0.07, 95% CI 0.02-0.22, P<0.001) (Table 12). 
Table 12. Logistic regression on the factors associated with mortality at 3 months. 
Variable OR 95% CI P-value
Age
     16-29 years 1 N.A. N.A.
     30-39 years 0.06 0.01-0.35 0.002
     40-49 years 0.19 0.05-0.75 0.017
NIHSS Score
     0-6 1 N.A. N.A.
     7-14 6.25 1.23-31.78 0.027
     >14 39.00 7.77-195.73 <0.001
Location
     Lobar 1 N.A. N.A.
     Deep 1.74 0.35-8.65 0.501
     Infratentorial 13.89 2.33-82.84 0.004
     Mixed 3.21 0.60-17.27 0.174
Hydrocephalus 4.00 1.61-9.90 0.003
Multiple hemorrhages 6.82 1.65-28.20 0.008
Brain herniation 5.94 1.71-20.60 0.005
Evacuation of hematoma 0.06 0.02-0.21 <0.001
Female gender (P=0.803), non-structural etiology (P=0.762), hematoma volume 0-29 mL 
(P=0.315), >60 mL (P=0.152), and IVH (P=0.152) are included, but not shown due to not reaching 
significance.
National Institutes of Health Stroke Scale, NIHSS; odds ratio, OR; confidential interval, CI
74
5 RESULTS
In the propensity-score nearest-neighbor matched analysis with matching criterion 
of ±0.28 difference, 3-month mortality was over three times higher among those 
not operated (27.5% vs. 7.8%, P<0.001). In comparison between the matched 
group, large hematomas (>60 mL) and herniation were more often present in those 
operated. A sensitivity analysis with a more strict criterion for matching (±0.03 
difference) and the groups entirely balanced resulted in a four-fold higher mortality 
in the non-surgical group (7.7% vs. 33.8% p<0.001) (Table 13). When the effect of 
hematoma evacuation on short-term mortality was analyzed separately in those 
with structural cause or non-structural cause underlying ICH, the differences did 
not reach statistically significant difference (2.4% vs. 11.9%, p=0.090, and 11.7% vs. 
23.2%, P=0.054, respectively), likely due to the relatively small number of patients.
Table 13. Propensity-score-matched comparison between patients with and without ICH 
evacuation. 
Analysis I Analysis II
Variable
ICH 
evacuated 
(n=102)
ICH not 
evacuated 
(n=102) P-value
ICH evacuated 
(n=65)
ICH not 
evacuated 
(n=65)
P-value
Sex 0.774 0.596
     Males 61 (59.8) 63 (61.8) 38 (58.5) 35 (53.8)
     Females 41 (40.2) 39 (38.2) 27 (41.5) 30 (46.2)
Age 0.876 0.911
     16-29 years 23 (22.5) 20 (19.6) 13 (20.0) 12 (18.5)
     30-39 years 23 (22.5) 24 (23.5) 14 (21.5) 16 (24.6)
     40-49 years 56 (54.9) 58 (56.9) 38 (58.5) 37 (56.9)
NIHSS Score 0.392 0.770
     0-6 39 (38.2) 46 (45.1) 23 (35.4) 27 (41.5)
     6-14 17 (16.7) 11 (10.8) 9 (13.8) 8 (12.3)
     >14 46 (45.1) 45 (44.1) 33 (50.8) 30 (46.2)
Structural etiology 42 (41.2) 41 (40.2) 0.887 23 (35.4) 26 (40.0) 0.587
Location of hemorrhage 0.096 0.800
     Lobar 19 (18.6) 24 (23.5) 14 (21.5) 15 (23.1)
     Deep 29 (28.4) 37 (36.3) 23 (35.4) 21 (32.3)
     Infratentorial 18 (17.6) 21 (20.6) 12 (18.5) 16 (24.6)
     Mixed 36 (35.3) 20 (19.6) 16 (24.6) 13 (20.0)
Volume of hemorrhage 0.002 0.848
     0-29 ml 48 (47.1) 65 (63.7) 40 (61.5) 43 (66.2)
     30-60 ml 23 (22.5) 26 (25.5) 13 (20.0) 12 (18.5)
     > 60 ml 31 (30.4) 11 (10.8) 12 (18.5) 10 (15.4)
IVH 42 (41.2) 37 (36.3) 0.472 25 (38.5) 26 (40.0) 0.857
Hydrocephalus 33 (32.4) 26 (25.5) 0.280 23 (35.4) 17 (26.2) 0.254
Multiple hemorrhages 3 (2.9) 5 (4.9) 0.471 3 (4.6) 3 (4.6) 1.000
Herniation 28 (27.5) 16 (15.7) 0.041 12 (18.5) 10 (15.4) 0.640
Mortality at 3 months 8 (7.8) 28 (27.5) <0.001 5 (7.7) 22 (33.8) <0.001
Nearest–neighbor-matched analysis was first conducted including all patients having hematoma 
evacuated (matching criterion of ±0.28 propensity score difference, analysis I), and subsequently, 
using more strict matching criterion of ±0.03 (analysis II).
Data are n (%)
National Institutes of Health Stroke Scale, NIHSS; intraventricular hemorrhage, IVH;  
intracerebral hemorrhage, ICH
5.3.3 Impact of medical complications on early mortality
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Arrhythmia, renal failure, hyperglycemia, and hypernatremia associated with 
increased 3-month mortality in univariate analysis (Table 11). In the logistic 
regression model with gender, age, hematoma volume, infratentorial location of 
hematoma, presence of IVH, NIHSS score at arrival, neurosurgical evacuation of 
hematoma performed and diabetes adjusted for, the only independent complication 
associated with mortality at 3 months was hyperglycemia, which increased the odds 
of dying nearly six-fold (OR 5.90, 95% CI 2.25-15.48, P<0.001). In the regression 
model with the number of separate complications as the covariate of interest, 3 or 
more complications independently were associated with the risk of death by over 
seven-fold increase (Table 14).
Table 14. Univariable and multivariable analysis on 3-month mortality with number of 
different complications. 
Factor 3-month 
mortality all 
55/325 (16.9%)
P-Value
OR (95% CI) P-value
Number of complications <0.001
        0 (n=66) 2 (3.0%) 1 N.A.
        1 (n=65) 1 (1.5%) 0.649 (0.05-8.40) 0.649
        2 (n=66) 16 (24.2%) 5.36 (0.90-31.86) 0.065
        3 or more (n=128) 36 (28.1%) 7.76 (1.42-42.48) 0.018
Multivariable analysis was adjusted for gender, hematoma volume, infratentorial location of 
hematoma, presence of intraventricular extension, arrival National Institutes of Health Stroke Scale 
score, and neurosurgical evacuation of hematoma.
OR, odds ratio; CI, confidence interval
5.4 POST-STROKE DEPRESSION
Of the 336 patients initially included in the Helsinki ICH in the Young Registry, 55 
(16.4%) had died in the first 30 days after ICH; 32 (9.5%) had died after that, 13 
(3.9%) lived abroad and were lost to follow-up; 101 (30.1%) declined to participate, 
4 (1.2%) withdrew their consent, and one (0.3%) was excluded due to severe aphasia 
and impaired cognition, leaving 130 eligible patients participating in the follow-up 
study of PSD. The median follow-up time was 9.7 (7.0-12.0) years. The follow-up 
interview was done for 130 (38.7%) (median age 50.3 [44.6-55.3] years) and a 
structural clinical examination for 76 (22.6%) patients (Figure 11). In those included, 
proportion of females was higher (48.5% vs 36.1%, P=0.049), etiology of ICH was 
more often structural (36.9% vs 20.2%, P=0.004) and NIHSS scores at arrival to 
hospital were lower (median 4 [1-11] vs. 9 [2-18], P=0.002).
PSD was present among 23.1% of patients, 40.0% had symptoms of anxiety, 
and pain-related anxiety was present among 19.2%. Mild, moderate, or severe 
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pain was present among 50.8%, 7.7%, and 0.8%, respectively. Those with more 
severe disability had higher scores in BDI-II (P=0.001), HADS (P=0.004), PASS-
20 (P=0.008), and BPI (P=0.003), while gender, follow-up time, and age at ICH 
onset were not associated with any of these. Those who had hematoma evacuation 
had lower BDI-II scores (P=0.031), BPI scores (P=0.008), and PASS-20 scores 
(P=0.001). Antidepressant medication was used by 9.2%. In addition to the one 
patient excluded from analyses of PSD, nobody suffered from severe cognitive 
impairment, while 3.9% suffered from moderate cognitive impairment, and 48.7% 
from mild cognitive impairment. Median MoCA score was 26, and interquartile 
range was between 22 and 28. MoCA scores decreased with higher age (P=0.004), 
and more severe disability (P<0.001), but no correlation was found with follow-
up time (P=0.325), gender (40 [53%] males, P=0.714), hematoma evacuation in 
comparison to conservative treatment (22.4% operated, P=0.522), or presence of 
PSD (P=0.119). 62% of our patients were currently employed.
In our univariate analysis, baseline hydrocephalus (P=0.014) was the only 
baseline factor associated with PSD in addition to higher BPI (P<0.001), PASS-20 
(P<0.001), and mRS scores (P=0.011), and being currently unemployed (P=0.027). 
In our multivariate model, adjusted for IVH for tending to associate with PSD 
(P=0.099), only hydrocephalus (OR 4.78, 95% CI 1.55-14.77, P=0.007), and PASS-
20 score (OR 1.05, 95% CI 1.03-1.08, P<0.001, per point) were independently 
associated with increased prevalence of PSD.
5.5 LONG-TERM MORTALITY, FUNCTIONAL OUTCOME,  
AND RECURRENT STROKE 
The mortality analysis included all but those dying in the first 30 days or lost to 
follow-up, numbering 268 (79.8%). Analysis of long-term functional outcome 
included ICH recurrence, post-ICH epilepsy, return to work, and residual symptoms 
of those 131 (39.0%) alive and willing to participate (Figure 11).
5.5.1 SURVIVAL
Among the 30-day survivors, 1-year survival was 98.1% (95% confidential interval 
[CI] 96.2-100%), 5-year survival 93.2% (95% CI 89.3-97.1%), and 10-year survival 
88.8% (95% CI 84.9%-92.7%). 
Factors associated with increased mortality in univariate analysis included male 
gender (HR 3.9, 95% CI 1.49-10.08, P=0.005), diabetes (HR 3.33, 95% CI 1.37-8.11, 
P=0.008), and IVH (OR 2.11, 95% CI 1.04-4.28, P=0.039. After Cox regression 
model adjusted for age and factors tending to associate with mortality in univariate 
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analysis (NIHSS score [P=0.094] and structural etiology [P=0.096]), higher risk of 
death was independently associated with male gender (OR 3.36, 95% CI 1.28-8.80, 
P=0.014) and diabetes (OR 2.64, 95% CI 1.01-6.89, P=0.047). Those with IVH (OR 
1.89, 95% CI 0.93-3.84, P=0.081) tended to die slightly earlier than those with no 
IVH after that adjustment. Mortality among diabetic males with IVH was higher 
than for females without diabetes and IVH (50.0% vs. 11.4%, p=0.018). Hematoma 
evacuation had no significant effect on long-term mortality when measured by 
Kaplan-Meyer survival analysis ((log rank P=0.326).
5.5.2 FUNCTIONAL OUTCOME
As Figure 15 shows, in mRS distribution of the 131 patients, 67 (51.1%) achieved 
favorable functional outcome (mRS 0 or 1). Median BI was 100 (IQR 100-100, 
range 15-100) with an association with age group (P=0.004), but no association 
with gender (P=0.470) or with hematoma evacuation (P=0.751). 
In the univariate analysis, increasing age (P<0.001), hypertension (P=0.004), 
presence of IVH (P=0.013), brain herniation (P=0.020), onset NIHSS score 
(P<0.001), and non-structural underlying etiology of ICH (P=0.048) were associated 
with unfavorable outcome. In the multivariate logistic regression analysis including 
these same covariates and other parameters with a univariate trend, hematoma 
volume (P=0.070), presence of hydrocephalus (P=0.067), surgical hematoma 
evacuation (P=0.061), as well as gender (P=0.669), we found that independent 
factors associated with poor outcome at follow-up were higher age (OR 1.09, 95% 
CI 1.03-1.15, P=0.002 per year), higher initial NIHSS score (OR 1.17, 95% CI 1.08-
1.27, P<0.001, per point), and IVH (OR 3.26, 95% CI 1.11-9.55, P=0.031).
5.5.3 STROKE RECURRENCE
Recurrent ICH occurred 12 times in 10 patients (7.6%), at a median of 3.9 (2.6-4.8) 
years after the index ICH. Etiology of initial and recurrent ICH was hypertension in 
2, cavernoma in 2, AVM in 2, Moya-Moya disease in 1, vasculitis in 1, and unknown 
in 2 patients. Ischemic stroke struck 4 patients (3.1%) at a median of 2.7 (1.4-4.1) 
years after the index ICH. Cumulative rate of ICH recurrence was 1.9% (95% CI 
0-3.8%) during the first year and 11.2% (95% CI 7.3-15.1%) at 10 years. 
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5.5.4 RETURN TO WORK
Of the 131 patients, 119 (90.8%) were employed before the ICH, and 63 (48.1%) were 
employed at follow-up. Rate of current employment was higher among younger 
patients: of 21 (75.0%) out of 28 patients aged 16-29;16 (61.5%) out of 26 patients 
aged 30-39; 25 (32.5%) out of 77 patients aged 40 to 49 years at ICH onset (P<0.001), 
but no association emerged between current employment and gender (P=0.324) 
or hematoma evacuation (P=0.879). 
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Figure 15. Functional outcome after intracerebral hemorrhage at a young age
Functional outcome according to age at ICH onset (p=0.007), NIHSS score at arrival (p<0.001), and intraventricular extension (p=0.100). Median age 
at follow-up was 50.3 [44.7-55.3] years, and 68 (51.9%) were men. 
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Figure 15. Functional outcome after intracerebral hemo rha e at a young age 
Functional  ording to age at ICH onset (p=0.007), NIHSS score at arrival (p<0.001), 
and intraventricular extension (P=0.100). Median age at follow-up was 50.3 [44.7-55.3] years, and 
68 (51.9%) were men.
5.5.5 DWELLING
Of the 131 patients, 110 (84.0%) were living in their homes without requiring 
assistance from outside their family, 14 (10.7%) required assistance in their daily 
living, and 7 (5.3%) were living under continuing institutional care. Those with 
favorable outcome were more often living at home without assistance (Table 15).
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Table 15. Residence and functional outcome after intracerebral hemorrhage at a 
young age
Factor At home without 
assistance (n=110)
At home with 
assistance (n=14)
Nursing home 
(n=7)
P-value
mRS <0.001
0 30 (27.3) 0 0
1 37 (33.6) 0 0
2 27 (24.5) 3 (21.4) 1 (14.3)
3 15 (13.6) 9 (64.3) 3 (42.9)
4 1 (0.9) 1 (7.1) 3 (42.9)
5 0 1 (7.1) 0
Data are n (%)
mRS, modified Rankin Scale
5.5.6 EPILEPSY
Pre-ICH epilepsy had been diagnosed among 4 (3.1%), and post-ICH epilepsy among 
30 (22.9%) patients, 27 (20.6%) of whom currently received AED. No association 
appeared between post-ICH epilepsy and hematoma evacuation (P=0.470). Early 
seizures within 7 days of ICH had occurred in 8 (6.1%) patients and late seizures 
(>7 days after ICH) in 22 (16.8%). The initial late seizure occurred with a median 
of 1.3 years (0.7-1.6) after ICH; early seizure occurred in 8 of 30 patients with 
post-ICH epilepsy (26.7%). The cumulative rate for late seizures was 5.1% (95% CI 
1.2-9.1%) during the first year following ICH, and 13.7% (95% CI 7.8-19.6%) during 
the following 10 years. Post-ICH epilepsy developed among 13 (36.1%) patients 
with lobar hematoma, 6 (11.8%) with deep hemispheric location, 1 (5.3%) with 
infratentorial, and 9 (45%) with mixed location (P=0.001).
5.5.7 RESIDUAL SYMPTOMS
Some level of one-sided motor dysfunction symptoms were reported by 55 (42.0%) 
patients, and some kind of one-sided sensory dysfunction by 52 (39.7%). Difficulties 
in producing or understanding speech were reported by 27 (20.6%), spasticity by 36 
(27.5%), visual field impairment by 21 (16.0%), and diplopia by 14 (10.7%). Sixty-
one (46.9%) patients reported to have currently less energy than before ICH, and 
5 (3.8%) patients reported difficulties to carry out daily activities due to fatigue. 
Mild difficulties with sleeping were reported by 53 (40.8%), and moderate or severe 
difficulties by another 24 patients (18.5%).
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5.5.8 QUALITY OF LIFE
Forty-six patients (35.4%) in total stated being in full health in terms of EQ-5D 
health state being 1-1-1-1-1, and the value for health 1. The median health value was 
0.824 (0.708-1) with range from 0.077 to 1. The distribution across the variables 
of EQ-5D are shown in Figure 16. Higher initial NIHSS score at baseline, as well 
as developed PSD and unfavorable outcome independently predicted worse quality 
of life (Tables 16 and 17).
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Figure 16. Quality of life of survivors of intracerebral hemorrhage at young age.
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Figure 16. Quality of life of survivors of intracerebral hemorrhage at young age.
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Table 16. Univariate analysis on factors associated with health-related quality  
of life measured by EQ-5D.
Factor Health value (95% CI) P-value
All 0.824 (0.708-1)
Males 0.818 (0.66-1) 0.372
Age group 0.006
         16-29 0.919 (0.818-1)
         30-39 0.824 (0.715-1)
         40-49 0.785 (0.655-1)
Hypertension 0.723 (0.618-0.826) <0.001
Diabetes 0.723 (0.592-0.785) 0.086
Cardiac disease 0.733 (0.627-0.879) 0.608
NIHSS score at arrival <0.001
         0-6 0.838 (0.793-1)
         7-14 0.723 (0.654-0.818)
         >14 0.66 (0.592-0.760)
Hematoma volume <0.001
         0-30 mL 0.824 (0.723-1)
         30-60 mL 0.723 (0.634-1)
         >60 mL 0.66 (0.624-0.747)
Infratentorial hematoma location 0.824 (0.721-0.879) 0.870
IVH 0.723 (0.654-0.919) 0.093
Hydrocephalus 0.794 (0.659-1) 0.425
Herniation 0.723 (0.658-0.797) 0.143
Multiple hemorrhages 0.886 (0.564-1) 0.858
PSD present 0.716 (0.626-0.803) <0.001
Unfavorable outcome (mRS 2-5) 0.706 (0.618-0.785) <0.001
Data are median (IQR)
Table 17. Linear regression analysis on factors associated with quality  
of health measured by EQ-5D health value.
Factor Unstandardized Coefficient 
for Health value (95% CI)
P-value
Male 0.031 (-0.014-0.077) 0.173
Age at onset per year -0.001 (-0.004-0.002) 0.375
NIHSS score at onset per point -0.004 (-0.008-[-0.001]) 0.016
Hematoma volume per 10 mL 0.003 (-0.007-0.014) 0.517
PSD present -0.089 (-0.144-[-0.033]) 0.002
Unfavorable outcome (mRS 2-5) -0.180 (-0.231-[0.129]) <0.001
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6 DISCUSSION
6.1 GENERAL DISCUSSION
In this study, a hospital-based registry of young adults with first-ever ICH was 
created and survivors were reevaluated by inviting for a follow-up visit. The database 
was linked to the national cause-of-death register to obtain reliable data on vital 
status. Until now, most data on ICH in the young have based on relatively small 
patient samples. We collected data on over 300 consecutive young patients with 
ICH and compared their risk factors, underlying causes, imaging, treatment, and 
outcome to over 900 older ICH patients in an existing database. To the best of 
our knowledge, we are the first to execute such a comparison. Moreover, data on 
functional outcome of survivors of ICH at young age have been practically absent. 
Our results therefore substantially improve our understanding of young-onset ICH. 
ICH in the young has been studied in a dozen hospital-based cohorts, two of 
which were published only very recently.110,244-254 These studies have been constructed 
in a similar pattern, by retrospectively defining the risk factors, causes, and mortality 
on the basis of chart notes and imaging archives. Distribution between sexes in our 
study (59.5% men and 40.5% women), and our results regarding the incidence of 
ICH are in line with previous studies, as well as on our finding that the incidence 
of ICH rises substantially after 40 years of age.16
6.2 RISK FACTORS AND CAUSES OF INTRACEREBRAL 
HEMORRHAGE IN THE YOUNG
The most common risk factor in our series was hypertension, followed by smoking, 
and excessive alcohol consumption, which was more common among our ICH 
patients than reported among Finnish population on average (9.8%).829 Our 
results regarding the prevalence of hypertension, smoking, and heavy drinking 
are consistent with previous studies of ICH in the young. Our results, however, 
also conclude that young victims of ICH have less cardiovascular risk factors, e.g. 
hypertension, diabetes, and cardiac diseases, than the elderly.
The most common etiology in our series, causing one-fourth of all ICH, was 
hypertensive microangiopathy, which has been reported from 11% to 79 %.109,252 
Structural lesions also caused approximately one-fourth of the ICH, having ranged 
from 17% to 65% in previous studies.110,245 These differences probably result from 
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small sample sizes, local settings, and non-uniform diagnostic strategies. According 
to our and others’ findings, the etiology underlying ICH at young age is far more 
often attributed to structural and rare causes as compared to elderly patients.109,246,247 
The cause underlying ICH, especially a structural or rare cause, was significantly 
more frequently defined, if both angiography and MRI was performed besides head 
CT. MRI and angiography should be, therefore, considered in routine basis on 
young adults with ICH.
6.3 SHORT-TERM MORTALITY AND PREDICTORS OF EARLY 
MORTALITY AFTER INTRACEREBRAL HEMORRHAGE
In perspective of other studies reporting high early mortality after ICH, the short-
term outcomes of our patients were fairly good. Over one-third were functionally 
independent at hospital discharge and 3-month mortality was less than 20%, 
substantially lower than that in the elderly. These findings are mostly in accordance 
with prior young ICH studies, although many of them have reported higher than 
20% early death rates. The prognosis thus appears to be much better in the young 
than in the elderly. ICH in the young appears less fatal compared to ICH in the 
elderly without a trend in hematoma volume by age. This may result from the 
facts that they have less comorbidities and more active treatment strategies carried 
out. Furthermore, our results indicate, that hematoma volume was independently 
associated with 3-month mortality only in the elderly. Reasons for this finding are 
unclear and further research is warranted.
The effect of neurosurgical intervention on mortality in patients with ICH has 
remained controversial so far. In our observational study, surgical hematoma 
evacuation was drastically associated with reduced 3-month mortality in young 
adults: their odds for dying were >90% lower as compared with non-surgically 
treated patients after adjusting for confounders. The relative risk reduction was 
71% lower even after comparison with propensity-matched patients who did not 
undergo hematoma evacuation. The effect of evacuation was assessed both by 
adjusting for confounders in a traditional logistic regression model and by comparing 
similar propensity-matched patients with and without intervention. In the latter 
comparison including patients who underwent hematoma evacuation, the most 
surprising observation was that those patients undergoing hematoma evacuation 
had larger hematoma volumes and more often brain herniation, and, despite 
these disadvantageous features, they fared better. These parameters should rather 
indicate higher mortality, as pointed out by multiple reports.10,275,277,281-283 The effect 
of surgical hematoma evacuation on short-term mortality in nonselected patients 
has been analyzed specifically in one retrospective study focusing on ICH in the 
young, and the finding was similar, yet not as striking as our results (OR 0.21 vs. 
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OR 0.06 in multivariable analysis).110 In clinical trials on the general population with 
ICH, however, no substantial difference between the death rates of those treated 
conservatively or with surgery has been found.432,433,484 Young patients, virtually 
absent in these trials, according to our results have often lesser risk factors and 
comorbidities, and therefore recover better from surgery in comparison to their elder 
counterparts. In our cohort, most patients undergoing evacuation of hematoma had 
a non-structural cause underlying ICH. Etiology underlying ICH being structural 
or not was included in our regression model, and in the nearest matching neighbor 
analysis. Structural causes were sufficiently frequent in propensity score analysis. 
In this regard the evacuation of hematoma was associated with better prognosis 
whether the cause was structural or not. Therefore, when significant deterioration 
occurs in a young patient with ICH and surgical options are considered, physicians 
should not make pessimistic treatment decisions based on negative randomized 
controlled trials, instead, an active approach seems to be in the best interest of 
these patients. Our results indicate that the value of surgical interventions needs 
to be tested separately in young patients in a future randomized controlled trials 
as benefit may be much higher in this subgroup.
Other independent factors associated with increased 3-month mortality on our 
study included more severe symptoms on admission, infratentorial hematoma 
location, hydrocephalus, herniation, and multiple hemorrhages. These are in 
accordance with other studies on general and young patients with ICH.76,109,110,274,275,279-
281,830 In patients with hydrocephalus, no difference was found in functional outcome 
if a ventriculostomy was placed in one study, a finding in accordance with ours.279
The distribution of locations of ICH has varied in previous studies on ICH in the 
young with lobar accounting for 25 to 55%, deep 22% to 50%, and infratentorial 16 to 
20%.109,110,251,830 Thus, our results are in accordance with prior findings. Furthermore, 
comparing with ICH in the general population, the distribution of ICH location 
seems similar at all ages. Multiple hemorrhages have been reported in 3% of young 
and general ICH patients, which is less than in our cohort (8%).109,110,831,832 In our 
study, intraventricular extension of hemorrhage was considerably more frequent 
than previously reported in the young (36% versus 3-4%).109,110 However, in the 
general population the results concerning the presence of IVH (41-57%) are similar 
to our finding.275,293,432,433
6.4 COMPLICATIONS OF INTRACEREBRAL HEMORRHAGE
Electrolyte and glucose disturbances, hyperglycemia and hyponatremia in particular, 
were common in the acute phase among young patients with ICH. After adjusting 
for confounders, only hyperglycemia was independently associated with increased 
3-month mortality. Infections were as well rather frequent, but young patients seem 
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to survive them. Importantly, increasing number of separate complications was 
associated with increasing odds for death. Our observations suggest that randomized 
trials aiming to investigate not only treatment of hyperglycemia in ICH but a holistic 
approach to treatment of medical complications to improve patient outcomes is 
warranted. Further, this finding underlines one of the mechanisms how stroke unit 
care reduces mortality rates as prevention and quick treatment of complications in 
stroke patients is a hallmark of well-organized stroke units.
Hyperglycemia has been reported to worsen the outcome after ICH, but the 
underlying mechanisms remain unresolved.312,313 One possibility is that hyperglycemia 
and diabetes may cause pathologic reaction on vasculature.165-167 Our and others’ 
results indicate that better understanding on the role and mechanisms of hazard 
of hyperglycemia is needed. Hypoglycemia in our cases most likely occurred due to 
excessive insulin treatment. The rates of hypoglycemia among stroke patients have 
not been previously reported. No association was observed with hypoglycemia and 
mortality, as was shown for ischemic stroke, which may have occurred due to our 
relatively small patient sample.567 The optimal criteria and method for treatment 
of hyperglycemia are not solidly defined, and should, be further investigated in a 
properly designed clinical trial.559,560
Potassium disturbances and outcome after ICH has not yet been previously 
studied. Prevalence of hyponatremia among ICH patients has been reported 15.6%, 
and it has been identified as a predictor of in-hospital mortality in a recent study.581 
Our findings, in contrast, suggest that hyponatremia or other individual electrolyte 
disturbances do not increase mortality in young ICH patients. Our results are also 
in contrast to previous studies reporting respiratory infections being associated 
with poor outcome in general patients with ICH or ischemic stroke.338,610,650,652,654,655 
Possible explanations include our patient sample being relatively small, young adults 
tolerating small electrolyte disturbances better than their elderly counterparts with 
more comorbidities, as well as more aggressive treatment strategies. Our results, 
however, are in line with previous studies regarding the incidence of respiratory 
infections, and they causing longer hospitalization.610,650
According to a previous report, UTI is more severe than pneumonia among 
patients with ICH, which is in contrary to our findings.654 Reason for this is also 
unclear, but this could be explained with UTIs being discovered early by routine 
urine samples and being treated effectively with antibiotics. Antibiotic treatment was 
initiated in half of our patients, which is markedly more than number of patients 
in which the infection site could be detected, suggesting that only a suspicion of 
an infection based on fever or mildly elevated inflammatory parameters frequently 
leads to administration of antimicrobial treatments. 
In regard of venous thrombotic events, more aggressive DVT surveillance is 
probably needed, since even in our series of young ICH patients, approximately 5% 
suffered from DVT or pulmonary embolism. By our results, no myocardial ischemic 
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in-hospital events were encountered and arrhythmias were considerably rare, which 
is in accordance to our previous report in nonselected ICH patients.833 Although 
arrhythmias were more common in those dying within 3 months, no significant 
correlation with short-term mortality was observed after adjusting for confounders, 
which is probably due to the low number of cardiac events (n=4). 
A recent study found chronic kidney failure in nearly one-third of general ICH 
patients and it was associated with higher mortality.330 Renal failure was associated 
with higher risk of death in our univariate analysis, but not after adjusting for other 
prognosticators. The relatively high number of renal failure observed in our study 
reflects the criteria we used and that many patients having renal failure even before 
ICH, but nevertheless, requires further studies in various ICH patient populations 
on the same topic.
6.5 LONG-TERM OUTCOME OF INTRACEREBRAL 
HEMORRHAGE AT YOUNG AGE
Among the 30-day survivors cumulative mortality 10 years after ICH was 
approximately 11%, with diabetes and male sex independently predicting shorter 
survival. Only half of the survivors achieved a favorable outcome, and less than 
half were by then employed. Higher age, more severe initial stroke, and IVH were 
prognostic factors for poor functional outcome, while hematoma volume and surgical 
evacuation of the hematoma were not independently associated with outcome.
Long-term survival of young ICH patients has been reported only once, very 
recently. Those investigators reported a cumulative 5-year mortality of 6.1%, 10-year 
mortality of 10.3%, and 20-year mortality of 13.7% among 91 patients surviving one 
month, findings in accordance with ours.730 In comparison to young adults with 
ischemic stroke, their reported 5-year mortality of 7.9% looks comparable to that 
of young ICH patients.731 Furthermore, long-term survival from ICH also appears 
to be markedly better among the young in comparison to general population, since 
a recent meta-analysis reported fewer than one-third surviving the first 5 years.263 
One possible explanation for this is that the young have fewer risk factors and 
comorbidities affecting survival, as we have shown. We identified male gender 
and diabetes as independent factors predicting survival, which have also been 
identified as prognostic for poor outcome in ischemic stroke, and diabetes specifically 
associated with increased mortality among ICH patients.284,319,720,721 Diabetes may 
cause deleterious effects on the microvasculature, resulting in hematoma expansion 
and impaired neuroregeneration.165-167
Regarding functional outcome among the young long-term survivors, our results 
are in agreement with those of the only study that has reported long-term functional 
outcome among young ICH patients: approximately half of the survivors achieved 
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an mRS score of 0 or 1.759 Poor functional outcome in 57% (mRS 3-5) and an 
independence rate of 47% among the acute-phase survivors has been reported 
for unselected ICH patients, implying that young patients recover better also with 
regard to functional outcome.266,281,321,834 
Several studies have investigated the predictors of functional outcome in the 
general ICH population, but with no studies concerning this issue particularly for 
young patients.93,266,281,286,321,431 With few differences, they have reported consistent 
prognostic factors for poor outcome: larger hematoma volume, IVE, infratentorial 
hematoma, more severe symptoms at arrival, and higher age. In our analysis, 
increasing age, initial symptom severity, and IVE were associated with unfavorable 
outcome at long-term follow-up. 
Our results concerning return to work are in line with the only study that has 
investigated this after young-onset ICH. They reported a 2- to 3-fold higher risk 
for unemployment than in the general population.760 Only 48.1% of our patients 
were employed at follow-up, despite the fact that more than half had no or only 
mild residual symptoms. This indicates that returning to modern-day vocational 
activity after young-onset ICH is a major challenge, and that need for and room for 
development in rehabilitation schemes may be unmet. Our findings on the quality 
of life of these patients support this.
A recent meta-analysis reported annual rates of recurrent ICH ranging from 1.3% 
to 7.4%.263,285,719,732-739 Age ≥65 years, lobar hematoma, and previous ischemic stroke 
have all been associated with increased risk for recurrence. These ICHs most likely 
resulted from hypertension or CAA. Our results indicate that the risk for recurrence 
is lower in a young than in a general ICH population. Reasons for this may include 
more frequent surgically-treatable structural causes underlying young-onset ICH, 
absence of CAA, and lower frequency of advanced small-vessel pathology. Due to the 
low number of recurrent events recorded in our series, independent prognosticators 
could not be analyzed.
Early seizures occurred approximately as often as in an unselected cohort of 
ICH patients. Late seizures, however, occurred more frequently among our young 
individuals (17%) than among our unselected ICH patients (9%).835 Reasons for this 
remain unresolved, but a possible explanation is those elderly with severe ICH more 
often dying in comparison to the young. Our results and others’ findings indicate 
that post-ICH epilepsy is associated with hematoma location.
PSD has been reported to occur in 30% of stroke survivors, with physical disability, 
stroke severity, hypertension, and cognitive impairment associated identified to 
predict PSD, which is in line with our findings.764-766,771,774,777,778 Hydrocephalus has 
not previously been reported to directly associate with PSD. This association seen 
in our patients may, therefore, be of chance. Hydrocephalus is, however, often 
associated with increased tissue damage, which could be the cause for PSD by both 
the pathophysiological and psychological mechanisms. More studies are needed 
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to draw conclusions on this matter, and to identify the underlying mechanisms. 
Current employment in our study was associated with decreased prevalence of PSD. 
This is in contrary to a recent retrospective study of young stroke patients.809 Those 
able to do work most likely have lesser disabilities, which quite certainly affects 
their mental health. According to our findings, those having surgical hematoma 
evacuation seem to have lesser symptoms of depression and pain, but no clear 
association with increased or decreased prevalence of PSD was found. Severity of 
PSD correlated with increased disability, which is in line with prior studies.
A major proportion of patients with PSD go untreated.798 Our findings support 
this notion, since only 9% received antidepressant medication, while PSD was 
present among 23%. The best benefiting patients for the use of antidepressants, 
as well as the optimal timing for antidepressant initiation is yet to be resolved.802,803 
6.6 STRENGTHS AND LIMITATIONS OF THE PRESENT STUDY
Our study has limitations. This is a single-center study. Our patient registry was 
collected retrospectively based on hospital records. Our criteria for hypertension 
may have resulted in some bias in the frequency of ICH related to hypertensive 
microangiopathy. Systematic autopsies were not performed in the study cohort 
and no uniform brain vascular imaging or MRI protocol was applied. Both of 
these factors may have led to underestimation of structural causes underlying ICH. 
The inclusion of ICH caused by tumor may have resulted in some selection bias, 
since not all diagnoses of tumor were included. Information regarding smoking or 
drinking habits lacked in almost half of our patients, likely due to their severe strokes 
hampering reliable communication. No definite uniform guidelines were available 
upon decision to pursue surgical treatment. Selecting only salvageable hematomas 
to be evacuated may have caused bias favoring surgery. It is possible that infective 
and thromboembolic complications may have occurred after the acute hospital 
period. The ascertainment of PE and DVT depended on the physician pursuing the 
diagnostic work-up, and clinically silent DVTs have probably also gone undetected. 
Due to low number of deaths, some of our multivariable estimates concerning 
impact of complications may be instable and should be interpreted with caution.
The main limitation of our follow-up study is that one-third of the invited 
patients did not wish to participate in the in-person follow-up, which may be due 
to being free from physical or emotional symptoms, and so our results in such 
areas as functional outcome should be treated with caution. Furthermore, some 
of the residual symptoms may have gone unrecorded in patients not examined in-
person. Those patients excluded from the follow-up study represented a group with 
more severe baseline deficits. Being too disabled was probably the major reason for 
declining. This may cause a shift towards those less disabled being included; we thus 
89
probably overestimated the true proportion of young ICH patients with favorable 
outcome. This makes ICH in the young an even more dismal disease than we are 
able to show. Since our sample size also was relatively small, our results, especially 
the effect of surgical hematoma evacuation, and association between hydrocephalus 
and PSD, should be confirmed in a larger prospective study.
Our study’s main strength is the large number of patients making it one of the 
largest young ICH series to date. Since our hospital serves as the only emergency unit 
for young stroke patients within the catchment area of 1.5 million inhabitants, our 
study is rather close to a population-based setting. We also have very detailed medical 
records based on strict legislation along with electronic imaging and laboratory 
archives facilitating data retrieval and in part compensating for the disadvantages 
of the study design. Further, our study, to the best of our knowledge, is the largest 
to date to include long-term data on young ICH patients, and it provides the longest 
median follow-up time.
6.7 IMPLICATIONS FOR PRACTICE AND FUTURE RESEARCH
Aggressive preventive measures against hypertension, smoking, and excessive 
alcohol use may be key in reducing risk of first-ever ICH and recurrences. Our 
data regarding imaging studies performed and establishment of the underlying 
cause behind ICH, suggests that MRI and vascular imaging should be considered 
in every young ICH patient. As most young ICH patients, even those with large 
hematoma, seem to survive their disease, nihilistic approaches, and decisions 
to limit or withdraw treatment should be avoided. Surgical treatment might 
be considered more often in these young patients, whether the cause of ICH is 
structural or not. It remains unresolved, however, should small hematomas be 
evacuated as well, and the optimal timing for surgery. Further randomized studies 
are needed to clarify these issues. Optimal strategy is needed to treat and avoid 
glucose disturbance and other medical complications in the acute phase. In regard 
of the long-term outcome, more effort in rehabilitation is needed to improve the 
functional outcomes of the survivors. Our study identified a few baseline factors 
that may prove useful in modifying long-term outcomes. Large-scale studies 
are warranted to confirm these results in this understudied patient population. 
Failing to do so may produce disastrous consequences such as unnecessary 
mortality and morbidity. ICH patients under rehabilitation, particularly those 
with severe disability, should also be more attentively followed at the outpatient 
clinic or rehabilitation unit, and treatment of PSD should be initiated earlier. 
Reason for hydrocephalus associating with late PSD remains unresolved, and 
this finding should be verified by another, prospective study.
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7 SUMMARY AND CONCLUSIONS
7 SUMMARY AND CONCLUSIONS
ICH at young age is rare, but catastrophic incident, with early death-rate being 
almost 20%, nevertheless less than among the elderly. Cardiovascular risk factors 
are relatively often present in young ICH patients, but the spectrum of causes differs 
to that of the elderly. Structural causes and hypertensive microangiopathy cause 
approximately half of ICH suffered, but rare causes must be kept in mind. ICH caused 
by medication or CAA are almost non-existent. After careful work-up, an assumed 
cause could be identified in most young ICH patients. Most predictors of short-term 
case-fatality are alike in young and elderly ICH patients, but the effect of hematoma 
volume is not as straightforward as it has been previously considered. In addition, 
initial hematoma evacuation was associated with substantially lower 3-month case-
fatality in young ICH patients. Hyperglycemia is a frequent complication of ICH 
in young adults and is independently associated with increased early mortality. 
However, a load of multiple separate complications increased mortality even further. 
A holistic, multidimensional strategy in their treatment, therefore, is imperative. Of 
every ten survivors of acute phase ICH at a young age, only one died within 10 years 
after onset, male sex and diabetes being associated with increased mortality. On 
the contrary, as many as half the survivors failed to achieve a favorable functional 
outcome, fewer than half were employed, and a fourth of the patients suffered from 
PSD. Factors predicting unfavorable outcome included increasing age, initial stroke 
severity, and IVH. These findings underline the grave importance to improve our 
current methods of rehabilitation, as well as to develop new and more effective 
methods. Treatment of depression also appears as an unmet need in young ICH 
survivors. Post-stroke fatigue, anxiety, pain, and sleeping difficulties were very 
common in this cohort.
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